[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fgVj2JlXxoXodVjsZw0_HnTyFoXZsodYnrLhxfkMtafg":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":9,"topConditions":12,"upcomingReadouts":34,"phaseBuckets":84,"rows":91},"ECOG-ACRIN Cancer Research Group",[4],116,false,50,25,154566,69,[13,16,19,21,24,26,29,31],{"name":14,"count":15},"Lung Cancer",9,{"name":17,"count":18},"Leukemia",7,{"name":20,"count":18},"Lymphoma",{"name":22,"count":23},"Melanoma (Skin)",5,{"name":25,"count":23},"Head and Neck Cancer",{"name":27,"count":28},"Breast Cancer",4,{"name":30,"count":28},"Invasive Breast Carcinoma",{"name":32,"count":33},"Anatomic Stage II Breast Cancer AJCC v8",3,[35,40,45,50,55,60,65,70,74,79],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT00003641","High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma","2015-01","interferon alfa-2b",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT01898494","Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer","2020-11-30","cisplatin",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT02445391","Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy","2021-04-07","Capecitabine",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT01824875","Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors","2021-05-26","temozolomide",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT01824836","A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)","2022-06-09","anastrozole",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT04001829","Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer","2023-09-19","Docetaxel",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT03419234","Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel","2024-01-08","Abiraterone Acetate",{"nctId":71,"briefTitle":72,"date":73,"intervention":49},"NCT02595424","Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas","2025-04-23",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT03504644","Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia","2025-07-22","Venetoclax",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT04484818","Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study","2026-06-30","Darolutamide",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,326,455,504,593,691,752,808,834,860,910,944,982,1008,1034,1060,1100,1122,1144,1206,1224,1242,1260,1278,1296,1322,1340,1358,1386,1404,1422,1440,1458,1476,1508,1526,1544,1562,1582,1620,1646,1668,1690,1738,1795,1817,1842,1860,1878,1896,1918,1936,1954,1972,1990,2008,2026,2044,2062,2080,2098,2122,2140,2158,2176,2207,2225,2243,2269,2294,2312,2337,2355,2373,2391,2409,2431,2453,2475,2493,2511,2529,2555,2573,2597,2622,2640,2658,2676,2694,2712,2730,2748,2766,2784,2802,2826,2844,2862,2880,2905,2923,2949,2967,3089,3169,3233,3281,3328,3358,3388,3414,3449,3480,3506,3528,3550,3572,3590,3614,3632,3662,3680,3698],{"intervention":93,"totalTrials":94,"cells":95},"Cisplatin",14,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":258,"PHASE4":310,"NA":312},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":28,"soonestReadout":43},[103,116,128,141,153,178,192,205,221,241],{"nctId":41,"briefTitle":42,"status":104,"phases":105,"primaryCompletion":43,"completion":106,"start":107,"enrollment":108,"conditions":109,"interventions":114},"ACTIVE_NOT_RECRUITING",[87],"2026-12","2014-01-22",519,[110,111,112,113],"Human Papilloma Virus Infection","Stage III Squamous Cell Carcinoma of the Oropharynx","Stage IVA Squamous Cell Carcinoma of the Oropharynx","Stage IVB Squamous Cell Carcinoma of the Oropharynx",[44,115],"carboplatin",{"nctId":117,"briefTitle":118,"status":119,"phases":120,"primaryCompletion":121,"completion":121,"start":122,"enrollment":98,"conditions":123,"interventions":125},"NCT02607423","Fludeoxyglucose F-18 PET\u002FCT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery","WITHDRAWN",[87],"2017-01-31","2015-11-19",[124],"Stage IIIA Non-Small Cell Lung Cancer",[93,64,126,127],"Gemcitabine Hydrochloride","Pemetrexed Disodium",{"nctId":71,"briefTitle":72,"status":104,"phases":129,"primaryCompletion":73,"completion":130,"start":131,"enrollment":132,"conditions":133,"interventions":137},[87],"2029-01-01","2015-11-06",67,[134,135,136],"Gastric Neuroendocrine Carcinoma","Intestinal Neuroendocrine Carcinoma","Pancreatic Neuroendocrine Carcinoma",[49,138,93,139,140],"Carboplatin","Etoposide","Temozolomide",{"nctId":142,"briefTitle":143,"status":144,"phases":145,"primaryCompletion":146,"completion":146,"start":147,"enrollment":148,"conditions":149,"interventions":152},"NCT03493425","Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery","RECRUITING",[87],"2029-03-31","2019-03-12",82,[150,151],"Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7","Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7",[138,93,64],{"nctId":154,"briefTitle":155,"status":144,"phases":156,"primaryCompletion":157,"completion":157,"start":158,"enrollment":159,"conditions":160,"interventions":177},"NCT02734537","Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery",[87],"2027-12-31","2016-11-23",189,[161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176],"Head and Neck Squamous Cell Carcinoma","Hypopharyngeal Squamous Cell Carcinoma","Laryngeal Squamous Cell Carcinoma","Laryngeal Squamous Cell Carcinoma, Spindle Cell Variant","Lip and Oral Cavity Squamous Cell Carcinoma","p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma","Stage III Hypopharyngeal Carcinoma AJCC v8","Stage III Laryngeal Cancer AJCC v8","Stage III Lip and Oral Cavity Cancer AJCC v8","Stage III Oral Cavity Verrucous Carcinoma","Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Stage IVA Hypopharyngeal Carcinoma AJCC v8","Stage IVA Laryngeal Cancer AJCC v8","Stage IVA Lip and Oral Cavity Cancer AJCC v8","Stage IVA Oral Cavity Verrucous Carcinoma","Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8",[93],{"nctId":179,"briefTitle":180,"status":181,"phases":182,"primaryCompletion":183,"completion":184,"start":185,"enrollment":186,"conditions":187,"interventions":189},"NCT00316888","Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer","COMPLETED",[87],"2015-11","2021-08-17","2007-02-28",63,[188],"Anal Cancer",[190,44,191],"cetuximab","fluorouracil",{"nctId":193,"briefTitle":194,"status":181,"phases":195,"primaryCompletion":196,"completion":197,"start":198,"enrollment":199,"conditions":200,"interventions":202},"NCT00003298","Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer",[87],"2010-02","2011-05","1999-06-01",39,[201],"Gastric Cancer",[44,191,203,204],"leucovorin calcium","paclitaxel",{"nctId":206,"briefTitle":207,"status":181,"phases":208,"primaryCompletion":209,"completion":210,"start":211,"enrollment":212,"conditions":213,"interventions":215},"NCT02412670","Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer",[87],"2018-08-23","2022-05-10","2015-08-27",36,[214],"High Grade Upper Tract Urothelial Carcinoma",[216,217,218,93,219,138,220],"Methotrexate","Vinblastine","Doxorubicin","Gemcitabine","Pegfilgrastim",{"nctId":222,"briefTitle":223,"status":224,"phases":225,"primaryCompletion":226,"completion":227,"start":228,"enrollment":229,"conditions":230,"interventions":238},"NCT02560298","Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer","UNKNOWN",[87],"2021-08-31","2023-08","2016-08-23",91,[231,232,233,234,235,236,237],"Anal Basaloid Carcinoma","Anal Canal Cloacogenic Carcinoma","Anal Squamous Cell Carcinoma","Metastatic Anal Canal Carcinoma","Recurrent Anal Canal Carcinoma","Stage IIIB Anal Canal Cancer","Stage IV Anal Canal Cancer",[49,138,93,239,240],"Fluorouracil","Paclitaxel",{"nctId":242,"briefTitle":243,"status":119,"phases":244,"primaryCompletion":245,"completion":245,"start":246,"enrollment":98,"conditions":247,"interventions":256},"NCT06084845","Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin\u002FCarboplatin for Patients With Head and Neck Cancer",[87],"2028-05-31","2024-04-12",[161,162,163,248,249,250,167,168,169,171,251,252,253,254,255],"Oral Cavity Squamous Cell Carcinoma","Oropharyngeal Squamous Cell Carcinoma","Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8","Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8","Stage IV Hypopharyngeal Carcinoma AJCC v8","Stage IV Laryngeal Cancer AJCC v8","Stage IV Lip and Oral Cavity Cancer AJCC v8","Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8",[138,93,257],"Xevinapant",{"trials":259,"activeCount":33,"soonestReadout":48},[260,276,294],{"nctId":261,"briefTitle":262,"status":104,"phases":263,"primaryCompletion":146,"completion":264,"start":265,"enrollment":266,"conditions":267,"interventions":274},"NCT05721755","Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck",[88],"2030-03-31","2023-06-08",290,[268,269,270,271,272,273,251,252,253,254,255],"Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Metastatic Head and Neck Squamous Cell Carcinoma","Metastatic Hypopharyngeal Squamous Cell Carcinoma","Metastatic Laryngeal Squamous Cell Carcinoma","Metastatic Oral Cavity Squamous Cell Carcinoma","Metastatic Oropharyngeal Squamous Cell Carcinoma",[138,93,239,240,275],"Pembrolizumab",{"nctId":46,"briefTitle":47,"status":104,"phases":277,"primaryCompletion":48,"completion":278,"start":279,"enrollment":280,"conditions":281,"interventions":293},[88],"2031-03-29","2015-10-20",415,[282,283,30,284,285,286,287,288,289,290,291,292],"Estrogen Receptor Negative","HER2\u002FNeu Negative","Progesterone Receptor Negative","Stage II Breast Cancer","Stage IIA Breast Cancer","Stage IIB Breast Cancer","Stage III Breast Cancer","Stage IIIA Breast Cancer","Stage IIIB Breast Cancer","Stage IIIC Breast Cancer","Triple-Negative Breast Carcinoma",[49,138,93],{"nctId":295,"briefTitle":296,"status":104,"phases":297,"primaryCompletion":298,"completion":299,"start":300,"enrollment":301,"conditions":302,"interventions":309},"NCT04559139","Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer",[87,88],"2028-07-01","2029-06-30","2021-02-24",186,[303,304,305,306,307,308],"Stage II Gallbladder Cancer AJCC v8","Stage IIA Gallbladder Cancer AJCC v8","Stage IIB Gallbladder Cancer AJCC v8","Stage III Gallbladder Cancer AJCC v8","Stage IIIA Gallbladder Cancer AJCC v8","Stage IIIB Gallbladder Cancer AJCC v8",[93,126],{"trials":311,"activeCount":98},[],{"trials":313,"activeCount":98},[314],{"nctId":315,"briefTitle":316,"status":181,"phases":317,"primaryCompletion":318,"completion":318,"start":319,"enrollment":320,"conditions":321,"interventions":322},"NCT01466257","Biomarkers in Patients With Head and Neck Cancer",[],"2012-01-01","2011-11-21",70,[25],[190,44,323,324,325],"DNA analysis","gene expression analysis","mutation analysis",{"intervention":239,"totalTrials":327,"cells":328},10,{"EARLY_PHASE1":329,"PHASE1":331,"PHASE2":333,"PHASE3":377,"PHASE4":451,"NA":453},{"trials":330,"activeCount":98},[],{"trials":332,"activeCount":98},[],{"trials":334,"activeCount":376,"soonestReadout":82},[335,349,364,368,372],{"nctId":336,"briefTitle":337,"status":104,"phases":338,"primaryCompletion":339,"completion":339,"start":340,"enrollment":341,"conditions":342,"interventions":347},"NCT04166318","Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study",[87],"2029-12-31","2020-01-02",252,[231,232,343,344,345,346],"Anal Canal Squamous Cell Carcinoma","Anal Margin Squamous Cell Carcinoma","Stage I Anal Cancer AJCC v8","Stage IIA Anal Cancer AJCC v8",[49,239,348],"Mitomycin",{"nctId":350,"briefTitle":351,"status":104,"phases":352,"primaryCompletion":82,"completion":353,"start":354,"enrollment":355,"conditions":356,"interventions":359},"NCT04233866","Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread",[87],"2026-12-31","2020-08-26",176,[357,358],"Metastatic Pancreatic Adenocarcinoma","Stage IV Pancreatic Cancer AJCC v8",[239,219,126,360,361,362,363],"Leucovorin","Leucovorin Calcium","Liposomal Irinotecan","Nab-paclitaxel",{"nctId":179,"briefTitle":180,"status":181,"phases":365,"primaryCompletion":183,"completion":184,"start":185,"enrollment":186,"conditions":366,"interventions":367},[87],[188],[190,44,191],{"nctId":193,"briefTitle":194,"status":181,"phases":369,"primaryCompletion":196,"completion":197,"start":198,"enrollment":199,"conditions":370,"interventions":371},[87],[201],[44,191,203,204],{"nctId":222,"briefTitle":223,"status":224,"phases":373,"primaryCompletion":226,"completion":227,"start":228,"enrollment":229,"conditions":374,"interventions":375},[87],[231,232,233,234,235,236,237],[49,138,93,239,240],2,{"trials":378,"activeCount":33,"soonestReadout":387},[379,383,407,419,437],{"nctId":261,"briefTitle":262,"status":104,"phases":380,"primaryCompletion":146,"completion":264,"start":265,"enrollment":266,"conditions":381,"interventions":382},[88],[268,269,270,271,272,273,251,252,253,254,255],[138,93,239,240,275],{"nctId":384,"briefTitle":385,"status":104,"phases":386,"primaryCompletion":387,"completion":387,"start":388,"enrollment":389,"conditions":390,"interventions":405},"NCT04248452","Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body",[88],"2028-03-31","2020-05-26",314,[391,392,393,394,395,396,397,398,399,400,401,402,403,404],"Clinical Stage IV Esophageal Adenocarcinoma AJCC v8","Clinical Stage IV Gastric Cancer AJCC v8","Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8","Clinical Stage IVA Gastric Cancer AJCC v8","Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8","Clinical Stage IVB Gastric Cancer AJCC v8","Metastatic Esophageal Adenocarcinoma","Metastatic Gastric Adenocarcinoma","Oligometastatic Esophageal Adenocarcinoma","Oligometastatic Gastric Adenocarcinoma","Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8","Pathologic Stage IV Gastric Cancer AJCC v8","Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8","Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8",[49,239,360,361,406],"Oxaliplatin",{"nctId":408,"briefTitle":409,"status":410,"phases":411,"primaryCompletion":412,"completion":413,"start":414,"enrollment":415,"conditions":416,"interventions":418},"NCT00002525","Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed","TERMINATED",[88],"2015-02","2015-04","1993-10-01",859,[417],"Colorectal Cancer",[191,203],{"nctId":420,"briefTitle":421,"status":144,"phases":422,"primaryCompletion":299,"completion":423,"start":424,"enrollment":425,"conditions":426,"interventions":431},"NCT05863195","Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial",[88],"2034-06-30","2023-10-19",408,[427,428,429,430],"Metastatic Colorectal Carcinoma","Metastatic Malignant Neoplasm in the Liver","Stage IV Colorectal Cancer AJCC v8","Unresectable Colorectal Carcinoma",[432,433,434,239,435,360,406,436],"Bevacizumab","Cetuximab","Floxuridine","Irinotecan","Panitumumab",{"nctId":438,"briefTitle":439,"status":410,"phases":440,"primaryCompletion":413,"completion":441,"start":442,"enrollment":443,"conditions":444,"interventions":448},"NCT00303628","Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer",[88],"2019-02-11","2006-05-11",355,[445,446,447],"Adenocarcinoma of the Rectum","Stage II Rectal Cancer","Stage III Rectal Cancer",[449,191,203,450],"oxaliplatin","bevacizumab",{"trials":452,"activeCount":98},[],{"trials":454,"activeCount":98},[],{"intervention":49,"totalTrials":456,"cells":457},6,{"EARLY_PHASE1":458,"PHASE1":460,"PHASE2":462,"PHASE3":490,"PHASE4":500,"NA":502},{"trials":459,"activeCount":98},[],{"trials":461,"activeCount":98},[],{"trials":463,"activeCount":33,"soonestReadout":53},[464,468,482,486],{"nctId":336,"briefTitle":337,"status":104,"phases":465,"primaryCompletion":339,"completion":339,"start":340,"enrollment":341,"conditions":466,"interventions":467},[87],[231,232,343,344,345,346],[49,239,348],{"nctId":51,"briefTitle":52,"status":104,"phases":469,"primaryCompletion":53,"completion":106,"start":470,"enrollment":471,"conditions":472,"interventions":480},[87],"2013-08-08",144,[473,474,475,476,477,478,479],"Gastrinoma","Glucagonoma","Insulinoma","Islet Cell Carcinoma","Pancreatic Polypeptide Tumor","Recurrent Islet Cell Carcinoma","Somatostatinoma",[54,481],"capecitabine",{"nctId":71,"briefTitle":72,"status":104,"phases":483,"primaryCompletion":73,"completion":130,"start":131,"enrollment":132,"conditions":484,"interventions":485},[87],[134,135,136],[49,138,93,139,140],{"nctId":222,"briefTitle":223,"status":224,"phases":487,"primaryCompletion":226,"completion":227,"start":228,"enrollment":229,"conditions":488,"interventions":489},[87],[231,232,233,234,235,236,237],[49,138,93,239,240],{"trials":491,"activeCount":376,"soonestReadout":48},[492,496],{"nctId":46,"briefTitle":47,"status":104,"phases":493,"primaryCompletion":48,"completion":278,"start":279,"enrollment":280,"conditions":494,"interventions":495},[88],[282,283,30,284,285,286,287,288,289,290,291,292],[49,138,93],{"nctId":384,"briefTitle":385,"status":104,"phases":497,"primaryCompletion":387,"completion":387,"start":388,"enrollment":389,"conditions":498,"interventions":499},[88],[391,392,393,394,395,396,397,398,399,400,401,402,403,404],[49,239,360,361,406],{"trials":501,"activeCount":98},[],{"trials":503,"activeCount":98},[],{"intervention":138,"totalTrials":505,"cells":506},12,{"EARLY_PHASE1":507,"PHASE1":509,"PHASE2":511,"PHASE3":548,"PHASE4":568,"NA":570},{"trials":508,"activeCount":98},[],{"trials":510,"activeCount":98},[],{"trials":512,"activeCount":33,"soonestReadout":43},[513,517,521,525,536,540,544],{"nctId":41,"briefTitle":42,"status":104,"phases":514,"primaryCompletion":43,"completion":106,"start":107,"enrollment":108,"conditions":515,"interventions":516},[87],[110,111,112,113],[44,115],{"nctId":71,"briefTitle":72,"status":104,"phases":518,"primaryCompletion":73,"completion":130,"start":131,"enrollment":132,"conditions":519,"interventions":520},[87],[134,135,136],[49,138,93,139,140],{"nctId":142,"briefTitle":143,"status":144,"phases":522,"primaryCompletion":146,"completion":146,"start":147,"enrollment":148,"conditions":523,"interventions":524},[87],[150,151],[138,93,64],{"nctId":526,"briefTitle":527,"status":181,"phases":528,"primaryCompletion":529,"completion":530,"start":531,"enrollment":320,"conditions":532,"interventions":533},"NCT00828009","BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery",[87],"2018-08-20","2019-05-22","2011-01-17",[14],[450,534,115,535,204],"Tecemotide","cyclophosphamide",{"nctId":206,"briefTitle":207,"status":181,"phases":537,"primaryCompletion":209,"completion":210,"start":211,"enrollment":212,"conditions":538,"interventions":539},[87],[214],[216,217,218,93,219,138,220],{"nctId":222,"briefTitle":223,"status":224,"phases":541,"primaryCompletion":226,"completion":227,"start":228,"enrollment":229,"conditions":542,"interventions":543},[87],[231,232,233,234,235,236,237],[49,138,93,239,240],{"nctId":242,"briefTitle":243,"status":119,"phases":545,"primaryCompletion":245,"completion":245,"start":246,"enrollment":98,"conditions":546,"interventions":547},[87],[161,162,163,248,249,250,167,168,169,171,251,252,253,254,255],[138,93,257],{"trials":549,"activeCount":376,"soonestReadout":48},[550,554,558],{"nctId":261,"briefTitle":262,"status":104,"phases":551,"primaryCompletion":146,"completion":264,"start":265,"enrollment":266,"conditions":552,"interventions":553},[88],[268,269,270,271,272,273,251,252,253,254,255],[138,93,239,240,275],{"nctId":46,"briefTitle":47,"status":104,"phases":555,"primaryCompletion":48,"completion":278,"start":279,"enrollment":280,"conditions":556,"interventions":557},[88],[282,283,30,284,285,286,287,288,289,290,291,292],[49,138,93],{"nctId":559,"briefTitle":560,"status":181,"phases":561,"primaryCompletion":562,"completion":184,"start":563,"enrollment":564,"conditions":565,"interventions":566},"NCT01107626","Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer",[88],"2019-01-31","2010-10-25",1516,[14],[240,138,432,567],"Pemetrexed Disodium Heptahydrate",{"trials":569,"activeCount":98},[],{"trials":571,"activeCount":98},[572,582],{"nctId":573,"briefTitle":574,"status":181,"phases":575,"primaryCompletion":576,"completion":576,"start":577,"enrollment":578,"conditions":579,"interventions":580},"NCT00898417","Biomarker Study of Blood Samples From Patients With Non-Small Cell Lung Cancer Treated With Carboplatin and Paclitaxel With or Without Bevacizumab",[],"2008-04-14","2008-03-14",90,[14],[450,115,204,581],"proteomic profiling",{"nctId":583,"briefTitle":584,"status":181,"phases":585,"primaryCompletion":586,"completion":586,"start":587,"enrollment":588,"conditions":589,"interventions":590},"NCT00900172","Study of Blood and Tissue Samples From Patients With Locally Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Treated With Bevacizumab, Carboplatin, and Paclitaxel",[],"2009-04-15","2008-03-15",180,[14],[450,115,204,324,591,592],"polymerase chain reaction","polymorphism analysis",{"intervention":64,"totalTrials":18,"cells":594},{"EARLY_PHASE1":595,"PHASE1":597,"PHASE2":599,"PHASE3":660,"PHASE4":687,"NA":689},{"trials":596,"activeCount":98},[],{"trials":598,"activeCount":98},[],{"trials":600,"activeCount":33,"soonestReadout":63},[601,627,631,635,648],{"nctId":61,"briefTitle":62,"status":104,"phases":602,"primaryCompletion":63,"completion":603,"start":604,"enrollment":605,"conditions":606,"interventions":626},[87],"2027-03-31","2019-08-09",249,[607,608,609,32,610,611,612,613,614,615,30,616,617,618,619,620,621,622,623,624,625],"Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage IA Breast Cancer AJCC v8","Anatomic Stage IB Breast Cancer AJCC v8","Anatomic Stage IIA Breast Cancer AJCC v8","Anatomic Stage IIB Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IIIA Breast Cancer AJCC v8","Anatomic Stage IIIB Breast Cancer AJCC v8","Anatomic Stage IIIC Breast Cancer AJCC v8","Prognostic Stage I Breast Cancer AJCC v8","Prognostic Stage IA Breast Cancer AJCC v8","Prognostic Stage IB Breast Cancer AJCC v8","Prognostic Stage II Breast Cancer AJCC v8","Prognostic Stage IIA Breast Cancer AJCC v8","Prognostic Stage IIB Breast Cancer AJCC v8","Prognostic Stage III Breast Cancer AJCC v8","Prognostic Stage IIIA Breast Cancer AJCC v8","Prognostic Stage IIIB Breast Cancer AJCC v8","Prognostic Stage IIIC Breast Cancer AJCC v8",[64,240],{"nctId":117,"briefTitle":118,"status":119,"phases":628,"primaryCompletion":121,"completion":121,"start":122,"enrollment":98,"conditions":629,"interventions":630},[87],[124],[93,64,126,127],{"nctId":142,"briefTitle":143,"status":144,"phases":632,"primaryCompletion":146,"completion":146,"start":147,"enrollment":148,"conditions":633,"interventions":634},[87],[150,151],[138,93,64],{"nctId":636,"briefTitle":637,"status":104,"phases":638,"primaryCompletion":639,"completion":640,"start":641,"enrollment":642,"conditions":643,"interventions":644},"NCT04266249","CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy",[87],"2026-10-31","2038-12-31","2020-03-13",2175,[32,610,611,613,30,619,620,621,623],[64,363,240,645,646,647],"Pertuzumab","Trastuzumab","Trastuzumab Emtansine",{"nctId":649,"briefTitle":650,"status":181,"phases":651,"primaryCompletion":652,"completion":413,"start":653,"enrollment":376,"conditions":654,"interventions":657},"NCT01824901","Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer",[86,87],"2014-07-09","2014-01-15",[655,656],"Recurrent Non-small Cell Lung Cancer","Squamous Cell Lung Cancer",[658,659],"docetaxel","AZD4547",{"trials":661,"activeCount":686,"soonestReadout":678},[662,674],{"nctId":663,"briefTitle":664,"status":181,"phases":665,"primaryCompletion":666,"completion":667,"start":668,"enrollment":669,"conditions":670,"interventions":672},"NCT00309985","Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer",[88],"2013-12-23","2025-01-31","2006-09-26",790,[671],"Metastatic Hormone-sensitive Prostate Cancer",[673,658],"androgen-deprivation therapy",{"nctId":675,"briefTitle":676,"status":104,"phases":677,"primaryCompletion":678,"completion":679,"start":680,"enrollment":681,"conditions":682,"interventions":684},"NCT05538663","Intravesical BCG vs GEMDOCE in NMIBC",[88],"2029-11-01","2030-10","2023-02-07",870,[683],"Non-muscle-invasive Bladder Cancer",[219,64,685],"Bacillus Calmette Guerin",1,{"trials":688,"activeCount":98},[],{"trials":690,"activeCount":98},[],{"intervention":692,"totalTrials":28,"cells":693},"Lenalidomide",{"EARLY_PHASE1":694,"PHASE1":696,"PHASE2":698,"PHASE3":713,"PHASE4":748,"NA":750},{"trials":695,"activeCount":98},[],{"trials":697,"activeCount":98},[],{"trials":699,"activeCount":98},[700],{"nctId":701,"briefTitle":702,"status":181,"phases":703,"primaryCompletion":704,"completion":704,"start":705,"enrollment":706,"conditions":707,"interventions":708},"NCT01216683","Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma",[87],"2019-12-02","2011-02-09",289,[20],[709,710,711,712],"rituximab","Bendamustin","bortezomib","lenalidomide",{"trials":714,"activeCount":33,"soonestReadout":353},[715,728,738],{"nctId":716,"briefTitle":717,"status":104,"phases":718,"primaryCompletion":353,"completion":719,"start":720,"enrollment":721,"conditions":722,"interventions":724},"NCT01863550","Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma",[88],"2034-02-05","2013-12-06",1087,[723],"Plasma Cell Myeloma",[725,726,727,692],"Bortezomib","Carfilzomib","Dexamethasone",{"nctId":729,"briefTitle":730,"status":144,"phases":731,"primaryCompletion":339,"completion":339,"start":732,"enrollment":733,"conditions":734,"interventions":736},"NCT03937635","Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma",[88],"2019-09-16",288,[735],"Smoldering Plasma Cell Myeloma",[737,727,692],"Daratumumab",{"nctId":739,"briefTitle":740,"status":144,"phases":741,"primaryCompletion":157,"completion":157,"start":300,"enrollment":742,"conditions":743,"interventions":746},"NCT04566328","Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial",[88],1450,[723,744,745],"RISS Stage I Plasma Cell Myeloma","RISS Stage II Plasma Cell Myeloma",[725,747,727,692],"Daratumumab and Hyaluronidase-fihj",{"trials":749,"activeCount":98},[],{"trials":751,"activeCount":98},[],{"intervention":275,"totalTrials":33,"cells":753},{"EARLY_PHASE1":754,"PHASE1":756,"PHASE2":758,"PHASE3":798,"PHASE4":804,"NA":806},{"trials":755,"activeCount":98},[],{"trials":757,"activeCount":98},[],{"trials":759,"activeCount":376,"soonestReadout":779},[760,775],{"nctId":761,"briefTitle":762,"status":104,"phases":763,"primaryCompletion":764,"completion":765,"start":766,"enrollment":767,"conditions":768,"interventions":771},"NCT03516279","Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease",[87],"2028-08-31","2031-08-31","2019-06-26",40,[769,770],"Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Minimal Residual Disease",[772,773,774,275],"Dasatinib","Imatinib Mesylate","Nilotinib",{"nctId":776,"briefTitle":777,"status":104,"phases":778,"primaryCompletion":779,"completion":780,"start":781,"enrollment":782,"conditions":783,"interventions":795},"NCT04462406","Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial",[87],"2027-01-31","2030-09-30","2021-02-09",150,[784,785,786,787,788,789,790,791,792,793,794],"Advanced Melanoma","Clinical Stage III Cutaneous Melanoma AJCC v8","Clinical Stage IV Cutaneous Melanoma AJCC v8","Melanoma of Unknown Primary","Pathologic Stage IIIB Cutaneous Melanoma AJCC v8","Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","Pathologic Stage IIID Cutaneous Melanoma AJCC v8","Pathologic Stage IV Cutaneous Melanoma AJCC v8","Unresectable Acral Lentiginous Melanoma","Unresectable Melanoma","Unresectable Mucosal Melanoma",[796,797,275],"Ipilimumab","Nivolumab",{"trials":799,"activeCount":686,"soonestReadout":146},[800],{"nctId":261,"briefTitle":262,"status":104,"phases":801,"primaryCompletion":146,"completion":264,"start":265,"enrollment":266,"conditions":802,"interventions":803},[88],[268,269,270,271,272,273,251,252,253,254,255],[138,93,239,240,275],{"trials":805,"activeCount":98},[],{"trials":807,"activeCount":98},[],{"intervention":727,"totalTrials":33,"cells":809},{"EARLY_PHASE1":810,"PHASE1":812,"PHASE2":814,"PHASE3":816,"PHASE4":830,"NA":832},{"trials":811,"activeCount":98},[],{"trials":813,"activeCount":98},[],{"trials":815,"activeCount":98},[],{"trials":817,"activeCount":33,"soonestReadout":353},[818,822,826],{"nctId":716,"briefTitle":717,"status":104,"phases":819,"primaryCompletion":353,"completion":719,"start":720,"enrollment":721,"conditions":820,"interventions":821},[88],[723],[725,726,727,692],{"nctId":729,"briefTitle":730,"status":144,"phases":823,"primaryCompletion":339,"completion":339,"start":732,"enrollment":733,"conditions":824,"interventions":825},[88],[735],[737,727,692],{"nctId":739,"briefTitle":740,"status":144,"phases":827,"primaryCompletion":157,"completion":157,"start":300,"enrollment":742,"conditions":828,"interventions":829},[88],[723,744,745],[725,747,727,692],{"trials":831,"activeCount":98},[],{"trials":833,"activeCount":98},[],{"intervention":360,"totalTrials":33,"cells":835},{"EARLY_PHASE1":836,"PHASE1":838,"PHASE2":840,"PHASE3":846,"PHASE4":856,"NA":858},{"trials":837,"activeCount":98},[],{"trials":839,"activeCount":98},[],{"trials":841,"activeCount":686,"soonestReadout":82},[842],{"nctId":350,"briefTitle":351,"status":104,"phases":843,"primaryCompletion":82,"completion":353,"start":354,"enrollment":355,"conditions":844,"interventions":845},[87],[357,358],[239,219,126,360,361,362,363],{"trials":847,"activeCount":376,"soonestReadout":387},[848,852],{"nctId":384,"briefTitle":385,"status":104,"phases":849,"primaryCompletion":387,"completion":387,"start":388,"enrollment":389,"conditions":850,"interventions":851},[88],[391,392,393,394,395,396,397,398,399,400,401,402,403,404],[49,239,360,361,406],{"nctId":420,"briefTitle":421,"status":144,"phases":853,"primaryCompletion":299,"completion":423,"start":424,"enrollment":425,"conditions":854,"interventions":855},[88],[427,428,429,430],[432,433,434,239,435,360,406,436],{"trials":857,"activeCount":98},[],{"trials":859,"activeCount":98},[],{"intervention":240,"totalTrials":15,"cells":861},{"EARLY_PHASE1":862,"PHASE1":864,"PHASE2":866,"PHASE3":888,"PHASE4":898,"NA":900},{"trials":863,"activeCount":98},[],{"trials":865,"activeCount":98},[],{"trials":867,"activeCount":376,"soonestReadout":63},[868,872,876,880,884],{"nctId":61,"briefTitle":62,"status":104,"phases":869,"primaryCompletion":63,"completion":603,"start":604,"enrollment":605,"conditions":870,"interventions":871},[87],[607,608,609,32,610,611,612,613,614,615,30,616,617,618,619,620,621,622,623,624,625],[64,240],{"nctId":193,"briefTitle":194,"status":181,"phases":873,"primaryCompletion":196,"completion":197,"start":198,"enrollment":199,"conditions":874,"interventions":875},[87],[201],[44,191,203,204],{"nctId":526,"briefTitle":527,"status":181,"phases":877,"primaryCompletion":529,"completion":530,"start":531,"enrollment":320,"conditions":878,"interventions":879},[87],[14],[450,534,115,535,204],{"nctId":222,"briefTitle":223,"status":224,"phases":881,"primaryCompletion":226,"completion":227,"start":228,"enrollment":229,"conditions":882,"interventions":883},[87],[231,232,233,234,235,236,237],[49,138,93,239,240],{"nctId":636,"briefTitle":637,"status":104,"phases":885,"primaryCompletion":639,"completion":640,"start":641,"enrollment":642,"conditions":886,"interventions":887},[87],[32,610,611,613,30,619,620,621,623],[64,363,240,645,646,647],{"trials":889,"activeCount":686,"soonestReadout":146},[890,894],{"nctId":261,"briefTitle":262,"status":104,"phases":891,"primaryCompletion":146,"completion":264,"start":265,"enrollment":266,"conditions":892,"interventions":893},[88],[268,269,270,271,272,273,251,252,253,254,255],[138,93,239,240,275],{"nctId":559,"briefTitle":560,"status":181,"phases":895,"primaryCompletion":562,"completion":184,"start":563,"enrollment":564,"conditions":896,"interventions":897},[88],[14],[240,138,432,567],{"trials":899,"activeCount":98},[],{"trials":901,"activeCount":98},[902,906],{"nctId":573,"briefTitle":574,"status":181,"phases":903,"primaryCompletion":576,"completion":576,"start":577,"enrollment":578,"conditions":904,"interventions":905},[],[14],[450,115,204,581],{"nctId":583,"briefTitle":584,"status":181,"phases":907,"primaryCompletion":586,"completion":586,"start":587,"enrollment":588,"conditions":908,"interventions":909},[],[14],[450,115,204,324,591,592],{"intervention":203,"totalTrials":23,"cells":911},{"EARLY_PHASE1":912,"PHASE1":914,"PHASE2":916,"PHASE3":926,"PHASE4":940,"NA":942},{"trials":913,"activeCount":98},[],{"trials":915,"activeCount":98},[],{"trials":917,"activeCount":686,"soonestReadout":82},[918,922],{"nctId":350,"briefTitle":351,"status":104,"phases":919,"primaryCompletion":82,"completion":353,"start":354,"enrollment":355,"conditions":920,"interventions":921},[87],[357,358],[239,219,126,360,361,362,363],{"nctId":193,"briefTitle":194,"status":181,"phases":923,"primaryCompletion":196,"completion":197,"start":198,"enrollment":199,"conditions":924,"interventions":925},[87],[201],[44,191,203,204],{"trials":927,"activeCount":686,"soonestReadout":387},[928,932,936],{"nctId":384,"briefTitle":385,"status":104,"phases":929,"primaryCompletion":387,"completion":387,"start":388,"enrollment":389,"conditions":930,"interventions":931},[88],[391,392,393,394,395,396,397,398,399,400,401,402,403,404],[49,239,360,361,406],{"nctId":408,"briefTitle":409,"status":410,"phases":933,"primaryCompletion":412,"completion":413,"start":414,"enrollment":415,"conditions":934,"interventions":935},[88],[417],[191,203],{"nctId":438,"briefTitle":439,"status":410,"phases":937,"primaryCompletion":413,"completion":441,"start":442,"enrollment":443,"conditions":938,"interventions":939},[88],[445,446,447],[449,191,203,450],{"trials":941,"activeCount":98},[],{"trials":943,"activeCount":98},[],{"intervention":219,"totalTrials":28,"cells":945},{"EARLY_PHASE1":946,"PHASE1":948,"PHASE2":950,"PHASE3":972,"PHASE4":978,"NA":980},{"trials":947,"activeCount":98},[],{"trials":949,"activeCount":98},[],{"trials":951,"activeCount":686,"soonestReadout":82},[952,956,968],{"nctId":350,"briefTitle":351,"status":104,"phases":953,"primaryCompletion":82,"completion":353,"start":354,"enrollment":355,"conditions":954,"interventions":955},[87],[357,358],[239,219,126,360,361,362,363],{"nctId":957,"briefTitle":958,"status":181,"phases":959,"primaryCompletion":960,"completion":961,"start":962,"enrollment":963,"conditions":964,"interventions":966},"NCT01164228","Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery",[87],"2020-03-30","2021-11-03","2010-09-17",87,[965],"Kidney Cancer",[219,967],"Sunitinib",{"nctId":206,"briefTitle":207,"status":181,"phases":969,"primaryCompletion":209,"completion":210,"start":211,"enrollment":212,"conditions":970,"interventions":971},[87],[214],[216,217,218,93,219,138,220],{"trials":973,"activeCount":686,"soonestReadout":678},[974],{"nctId":675,"briefTitle":676,"status":104,"phases":975,"primaryCompletion":678,"completion":679,"start":680,"enrollment":681,"conditions":976,"interventions":977},[88],[683],[219,64,685],{"trials":979,"activeCount":98},[],{"trials":981,"activeCount":98},[],{"intervention":725,"totalTrials":33,"cells":983},{"EARLY_PHASE1":984,"PHASE1":986,"PHASE2":988,"PHASE3":994,"PHASE4":1004,"NA":1006},{"trials":985,"activeCount":98},[],{"trials":987,"activeCount":98},[],{"trials":989,"activeCount":98},[990],{"nctId":701,"briefTitle":702,"status":181,"phases":991,"primaryCompletion":704,"completion":704,"start":705,"enrollment":706,"conditions":992,"interventions":993},[87],[20],[709,710,711,712],{"trials":995,"activeCount":376,"soonestReadout":353},[996,1000],{"nctId":716,"briefTitle":717,"status":104,"phases":997,"primaryCompletion":353,"completion":719,"start":720,"enrollment":721,"conditions":998,"interventions":999},[88],[723],[725,726,727,692],{"nctId":739,"briefTitle":740,"status":144,"phases":1001,"primaryCompletion":157,"completion":157,"start":300,"enrollment":742,"conditions":1002,"interventions":1003},[88],[723,744,745],[725,747,727,692],{"trials":1005,"activeCount":98},[],{"trials":1007,"activeCount":98},[],{"intervention":406,"totalTrials":33,"cells":1009},{"EARLY_PHASE1":1010,"PHASE1":1012,"PHASE2":1014,"PHASE3":1016,"PHASE4":1030,"NA":1032},{"trials":1011,"activeCount":98},[],{"trials":1013,"activeCount":98},[],{"trials":1015,"activeCount":98},[],{"trials":1017,"activeCount":376,"soonestReadout":387},[1018,1022,1026],{"nctId":384,"briefTitle":385,"status":104,"phases":1019,"primaryCompletion":387,"completion":387,"start":388,"enrollment":389,"conditions":1020,"interventions":1021},[88],[391,392,393,394,395,396,397,398,399,400,401,402,403,404],[49,239,360,361,406],{"nctId":420,"briefTitle":421,"status":144,"phases":1023,"primaryCompletion":299,"completion":423,"start":424,"enrollment":425,"conditions":1024,"interventions":1025},[88],[427,428,429,430],[432,433,434,239,435,360,406,436],{"nctId":438,"briefTitle":439,"status":410,"phases":1027,"primaryCompletion":413,"completion":441,"start":442,"enrollment":443,"conditions":1028,"interventions":1029},[88],[445,446,447],[449,191,203,450],{"trials":1031,"activeCount":98},[],{"trials":1033,"activeCount":98},[],{"intervention":126,"totalTrials":33,"cells":1035},{"EARLY_PHASE1":1036,"PHASE1":1038,"PHASE2":1040,"PHASE3":1050,"PHASE4":1056,"NA":1058},{"trials":1037,"activeCount":98},[],{"trials":1039,"activeCount":98},[],{"trials":1041,"activeCount":686,"soonestReadout":82},[1042,1046],{"nctId":117,"briefTitle":118,"status":119,"phases":1043,"primaryCompletion":121,"completion":121,"start":122,"enrollment":98,"conditions":1044,"interventions":1045},[87],[124],[93,64,126,127],{"nctId":350,"briefTitle":351,"status":104,"phases":1047,"primaryCompletion":82,"completion":353,"start":354,"enrollment":355,"conditions":1048,"interventions":1049},[87],[357,358],[239,219,126,360,361,362,363],{"trials":1051,"activeCount":686,"soonestReadout":298},[1052],{"nctId":295,"briefTitle":296,"status":104,"phases":1053,"primaryCompletion":298,"completion":299,"start":300,"enrollment":301,"conditions":1054,"interventions":1055},[87,88],[303,304,305,306,307,308],[93,126],{"trials":1057,"activeCount":98},[],{"trials":1059,"activeCount":98},[],{"intervention":1061,"totalTrials":376,"cells":1062},"Goserelin Acetate",{"EARLY_PHASE1":1063,"PHASE1":1065,"PHASE2":1067,"PHASE3":1069,"PHASE4":1096,"NA":1098},{"trials":1064,"activeCount":98},[],{"trials":1066,"activeCount":98},[],{"trials":1068,"activeCount":98},[],{"trials":1070,"activeCount":376,"soonestReadout":82},[1071,1080],{"nctId":80,"briefTitle":81,"status":104,"phases":1072,"primaryCompletion":82,"completion":245,"start":1073,"enrollment":1074,"conditions":1075,"interventions":1077},[88],"2021-03-01",27,[1076],"Prostate Carcinoma",[83,1061,1078,1079],"Leuprolide Acetate","Triptorelin",{"nctId":1081,"briefTitle":1082,"status":144,"phases":1083,"primaryCompletion":1084,"completion":1084,"start":1085,"enrollment":1086,"conditions":1087,"interventions":1092},"NCT04423211","Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging",[88],"2032-12-31","2020-10-08",804,[1088,1089,1090,1091],"Biochemically Recurrent Prostate Carcinoma","Metastatic Prostate Carcinoma","Prostate Adenocarcinoma","Stage IVB Prostate Cancer AJCC v8",[1093,1094,1061,1078,1095,1079],"Apalutamide","Degarelix","Relugolix",{"trials":1097,"activeCount":98},[],{"trials":1099,"activeCount":98},[],{"intervention":1078,"totalTrials":376,"cells":1101},{"EARLY_PHASE1":1102,"PHASE1":1104,"PHASE2":1106,"PHASE3":1108,"PHASE4":1118,"NA":1120},{"trials":1103,"activeCount":98},[],{"trials":1105,"activeCount":98},[],{"trials":1107,"activeCount":98},[],{"trials":1109,"activeCount":376,"soonestReadout":82},[1110,1114],{"nctId":80,"briefTitle":81,"status":104,"phases":1111,"primaryCompletion":82,"completion":245,"start":1073,"enrollment":1074,"conditions":1112,"interventions":1113},[88],[1076],[83,1061,1078,1079],{"nctId":1081,"briefTitle":1082,"status":144,"phases":1115,"primaryCompletion":1084,"completion":1084,"start":1085,"enrollment":1086,"conditions":1116,"interventions":1117},[88],[1088,1089,1090,1091],[1093,1094,1061,1078,1095,1079],{"trials":1119,"activeCount":98},[],{"trials":1121,"activeCount":98},[],{"intervention":1079,"totalTrials":376,"cells":1123},{"EARLY_PHASE1":1124,"PHASE1":1126,"PHASE2":1128,"PHASE3":1130,"PHASE4":1140,"NA":1142},{"trials":1125,"activeCount":98},[],{"trials":1127,"activeCount":98},[],{"trials":1129,"activeCount":98},[],{"trials":1131,"activeCount":376,"soonestReadout":82},[1132,1136],{"nctId":80,"briefTitle":81,"status":104,"phases":1133,"primaryCompletion":82,"completion":245,"start":1073,"enrollment":1074,"conditions":1134,"interventions":1135},[88],[1076],[83,1061,1078,1079],{"nctId":1081,"briefTitle":1082,"status":144,"phases":1137,"primaryCompletion":1084,"completion":1084,"start":1085,"enrollment":1086,"conditions":1138,"interventions":1139},[88],[1088,1089,1090,1091],[1093,1094,1061,1078,1095,1079],{"trials":1141,"activeCount":98},[],{"trials":1143,"activeCount":98},[],{"intervention":709,"totalTrials":23,"cells":1145},{"EARLY_PHASE1":1146,"PHASE1":1148,"PHASE2":1150,"PHASE3":1182,"PHASE4":1193,"NA":1195},{"trials":1147,"activeCount":98},[],{"trials":1149,"activeCount":98},[],{"trials":1151,"activeCount":686,"soonestReadout":353},[1152,1156,1171],{"nctId":701,"briefTitle":702,"status":181,"phases":1153,"primaryCompletion":704,"completion":704,"start":705,"enrollment":706,"conditions":1154,"interventions":1155},[87],[20],[709,710,711,712],{"nctId":1157,"briefTitle":1158,"status":104,"phases":1159,"primaryCompletion":353,"completion":353,"start":1160,"enrollment":1161,"conditions":1162,"interventions":1165},"NCT04115631","A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma",[87],"2019-12-13",360,[1163,1164],"Liver Lymphoma","Mantle Cell Lymphoma",[1166,1167,1168,1169,1170],"Acalabrutinib","Bendamustine","Bendamustine Hydrochloride","Cytarabine","Rituximab",{"nctId":1172,"briefTitle":1173,"status":410,"phases":1174,"primaryCompletion":1175,"completion":1175,"start":1176,"enrollment":1177,"conditions":1178,"interventions":1180},"NCT01013961","Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia",[87],"2015-04-14","2011-04-27",31,[1179],"Chronic Lymphocytic Leukemia",[1181,709],"alemtuzumab",{"trials":1183,"activeCount":686,"soonestReadout":779},[1184],{"nctId":1185,"briefTitle":1186,"status":104,"phases":1187,"primaryCompletion":779,"completion":779,"start":1188,"enrollment":1189,"conditions":1190,"interventions":1191},"NCT03267433","Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission",[88],"2017-11-27",689,[1164],[1170,1192],"Rituximab and Hyaluronidase Human",{"trials":1194,"activeCount":98},[],{"trials":1196,"activeCount":98},[1197],{"nctId":1198,"briefTitle":1199,"status":181,"phases":1200,"primaryCompletion":1201,"completion":1201,"start":1202,"enrollment":1203,"conditions":1204,"interventions":1205},"NCT01381705","Biomarkers in Predicting Response to Rituximab Treatment in Samples From Patients With Indolent Follicular Lymphoma",[],"2012-07-06","2012-02-06",259,[20],[709,323,324,592],{"intervention":726,"totalTrials":686,"cells":1207},{"EARLY_PHASE1":1208,"PHASE1":1210,"PHASE2":1212,"PHASE3":1214,"PHASE4":1220,"NA":1222},{"trials":1209,"activeCount":98},[],{"trials":1211,"activeCount":98},[],{"trials":1213,"activeCount":98},[],{"trials":1215,"activeCount":686,"soonestReadout":353},[1216],{"nctId":716,"briefTitle":717,"status":104,"phases":1217,"primaryCompletion":353,"completion":719,"start":720,"enrollment":721,"conditions":1218,"interventions":1219},[88],[723],[725,726,727,692],{"trials":1221,"activeCount":98},[],{"trials":1223,"activeCount":98},[],{"intervention":83,"totalTrials":686,"cells":1225},{"EARLY_PHASE1":1226,"PHASE1":1228,"PHASE2":1230,"PHASE3":1232,"PHASE4":1238,"NA":1240},{"trials":1227,"activeCount":98},[],{"trials":1229,"activeCount":98},[],{"trials":1231,"activeCount":98},[],{"trials":1233,"activeCount":686,"soonestReadout":82},[1234],{"nctId":80,"briefTitle":81,"status":104,"phases":1235,"primaryCompletion":82,"completion":245,"start":1073,"enrollment":1074,"conditions":1236,"interventions":1237},[88],[1076],[83,1061,1078,1079],{"trials":1239,"activeCount":98},[],{"trials":1241,"activeCount":98},[],{"intervention":1093,"totalTrials":686,"cells":1243},{"EARLY_PHASE1":1244,"PHASE1":1246,"PHASE2":1248,"PHASE3":1250,"PHASE4":1256,"NA":1258},{"trials":1245,"activeCount":98},[],{"trials":1247,"activeCount":98},[],{"trials":1249,"activeCount":98},[],{"trials":1251,"activeCount":686,"soonestReadout":1084},[1252],{"nctId":1081,"briefTitle":1082,"status":144,"phases":1253,"primaryCompletion":1084,"completion":1084,"start":1085,"enrollment":1086,"conditions":1254,"interventions":1255},[88],[1088,1089,1090,1091],[1093,1094,1061,1078,1095,1079],{"trials":1257,"activeCount":98},[],{"trials":1259,"activeCount":98},[],{"intervention":1094,"totalTrials":686,"cells":1261},{"EARLY_PHASE1":1262,"PHASE1":1264,"PHASE2":1266,"PHASE3":1268,"PHASE4":1274,"NA":1276},{"trials":1263,"activeCount":98},[],{"trials":1265,"activeCount":98},[],{"trials":1267,"activeCount":98},[],{"trials":1269,"activeCount":686,"soonestReadout":1084},[1270],{"nctId":1081,"briefTitle":1082,"status":144,"phases":1271,"primaryCompletion":1084,"completion":1084,"start":1085,"enrollment":1086,"conditions":1272,"interventions":1273},[88],[1088,1089,1090,1091],[1093,1094,1061,1078,1095,1079],{"trials":1275,"activeCount":98},[],{"trials":1277,"activeCount":98},[],{"intervention":1095,"totalTrials":686,"cells":1279},{"EARLY_PHASE1":1280,"PHASE1":1282,"PHASE2":1284,"PHASE3":1286,"PHASE4":1292,"NA":1294},{"trials":1281,"activeCount":98},[],{"trials":1283,"activeCount":98},[],{"trials":1285,"activeCount":98},[],{"trials":1287,"activeCount":686,"soonestReadout":1084},[1288],{"nctId":1081,"briefTitle":1082,"status":144,"phases":1289,"primaryCompletion":1084,"completion":1084,"start":1085,"enrollment":1086,"conditions":1290,"interventions":1291},[88],[1088,1089,1090,1091],[1093,1094,1061,1078,1095,1079],{"trials":1293,"activeCount":98},[],{"trials":1295,"activeCount":98},[],{"intervention":1297,"totalTrials":686,"cells":1298},"Cabozantinib",{"EARLY_PHASE1":1299,"PHASE1":1301,"PHASE2":1303,"PHASE3":1305,"PHASE4":1318,"NA":1320},{"trials":1300,"activeCount":98},[],{"trials":1302,"activeCount":98},[],{"trials":1304,"activeCount":98},[],{"trials":1306,"activeCount":686,"soonestReadout":780},[1307],{"nctId":1308,"briefTitle":1309,"status":144,"phases":1310,"primaryCompletion":780,"completion":780,"start":1311,"enrollment":1312,"conditions":1313,"interventions":1315},"NCT06475989","Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer",[88],"2024-08-22",264,[1314],"Refractory Differentiated Thyroid Gland Carcinoma",[1297,1316,1317],"Dabrafenib","Trametinib",{"trials":1319,"activeCount":98},[],{"trials":1321,"activeCount":98},[],{"intervention":1316,"totalTrials":686,"cells":1323},{"EARLY_PHASE1":1324,"PHASE1":1326,"PHASE2":1328,"PHASE3":1330,"PHASE4":1336,"NA":1338},{"trials":1325,"activeCount":98},[],{"trials":1327,"activeCount":98},[],{"trials":1329,"activeCount":98},[],{"trials":1331,"activeCount":686,"soonestReadout":780},[1332],{"nctId":1308,"briefTitle":1309,"status":144,"phases":1333,"primaryCompletion":780,"completion":780,"start":1311,"enrollment":1312,"conditions":1334,"interventions":1335},[88],[1314],[1297,1316,1317],{"trials":1337,"activeCount":98},[],{"trials":1339,"activeCount":98},[],{"intervention":1317,"totalTrials":686,"cells":1341},{"EARLY_PHASE1":1342,"PHASE1":1344,"PHASE2":1346,"PHASE3":1348,"PHASE4":1354,"NA":1356},{"trials":1343,"activeCount":98},[],{"trials":1345,"activeCount":98},[],{"trials":1347,"activeCount":98},[],{"trials":1349,"activeCount":686,"soonestReadout":780},[1350],{"nctId":1308,"briefTitle":1309,"status":144,"phases":1351,"primaryCompletion":780,"completion":780,"start":1311,"enrollment":1312,"conditions":1352,"interventions":1353},[88],[1314],[1297,1316,1317],{"trials":1355,"activeCount":98},[],{"trials":1357,"activeCount":98},[],{"intervention":1359,"totalTrials":686,"cells":1360},"Standard of Care Chemotherapy",{"EARLY_PHASE1":1361,"PHASE1":1363,"PHASE2":1365,"PHASE3":1367,"PHASE4":1382,"NA":1384},{"trials":1362,"activeCount":98},[],{"trials":1364,"activeCount":98},[],{"trials":1366,"activeCount":98},[],{"trials":1368,"activeCount":686,"soonestReadout":1373},[1369],{"nctId":1370,"briefTitle":1371,"status":144,"phases":1372,"primaryCompletion":1373,"completion":1373,"start":1374,"enrollment":1375,"conditions":1376,"interventions":1380},"NCT07001748","Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity",[87,88],"2030-05-30","2025-08-19",148,[1377,1378,1379],"Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma","Peritoneal Carcinomatosis",[1359,1381],"Intraperitoneal Paclitaxel",{"trials":1383,"activeCount":98},[],{"trials":1385,"activeCount":98},[],{"intervention":1381,"totalTrials":686,"cells":1387},{"EARLY_PHASE1":1388,"PHASE1":1390,"PHASE2":1392,"PHASE3":1394,"PHASE4":1400,"NA":1402},{"trials":1389,"activeCount":98},[],{"trials":1391,"activeCount":98},[],{"trials":1393,"activeCount":98},[],{"trials":1395,"activeCount":686,"soonestReadout":1373},[1396],{"nctId":1370,"briefTitle":1371,"status":144,"phases":1397,"primaryCompletion":1373,"completion":1373,"start":1374,"enrollment":1375,"conditions":1398,"interventions":1399},[87,88],[1377,1378,1379],[1359,1381],{"trials":1401,"activeCount":98},[],{"trials":1403,"activeCount":98},[],{"intervention":737,"totalTrials":686,"cells":1405},{"EARLY_PHASE1":1406,"PHASE1":1408,"PHASE2":1410,"PHASE3":1412,"PHASE4":1418,"NA":1420},{"trials":1407,"activeCount":98},[],{"trials":1409,"activeCount":98},[],{"trials":1411,"activeCount":98},[],{"trials":1413,"activeCount":686,"soonestReadout":339},[1414],{"nctId":729,"briefTitle":730,"status":144,"phases":1415,"primaryCompletion":339,"completion":339,"start":732,"enrollment":733,"conditions":1416,"interventions":1417},[88],[735],[737,727,692],{"trials":1419,"activeCount":98},[],{"trials":1421,"activeCount":98},[],{"intervention":434,"totalTrials":686,"cells":1423},{"EARLY_PHASE1":1424,"PHASE1":1426,"PHASE2":1428,"PHASE3":1430,"PHASE4":1436,"NA":1438},{"trials":1425,"activeCount":98},[],{"trials":1427,"activeCount":98},[],{"trials":1429,"activeCount":98},[],{"trials":1431,"activeCount":686,"soonestReadout":299},[1432],{"nctId":420,"briefTitle":421,"status":144,"phases":1433,"primaryCompletion":299,"completion":423,"start":424,"enrollment":425,"conditions":1434,"interventions":1435},[88],[427,428,429,430],[432,433,434,239,435,360,406,436],{"trials":1437,"activeCount":98},[],{"trials":1439,"activeCount":98},[],{"intervention":435,"totalTrials":686,"cells":1441},{"EARLY_PHASE1":1442,"PHASE1":1444,"PHASE2":1446,"PHASE3":1448,"PHASE4":1454,"NA":1456},{"trials":1443,"activeCount":98},[],{"trials":1445,"activeCount":98},[],{"trials":1447,"activeCount":98},[],{"trials":1449,"activeCount":686,"soonestReadout":299},[1450],{"nctId":420,"briefTitle":421,"status":144,"phases":1451,"primaryCompletion":299,"completion":423,"start":424,"enrollment":425,"conditions":1452,"interventions":1453},[88],[427,428,429,430],[432,433,434,239,435,360,406,436],{"trials":1455,"activeCount":98},[],{"trials":1457,"activeCount":98},[],{"intervention":436,"totalTrials":686,"cells":1459},{"EARLY_PHASE1":1460,"PHASE1":1462,"PHASE2":1464,"PHASE3":1466,"PHASE4":1472,"NA":1474},{"trials":1461,"activeCount":98},[],{"trials":1463,"activeCount":98},[],{"trials":1465,"activeCount":98},[],{"trials":1467,"activeCount":686,"soonestReadout":299},[1468],{"nctId":420,"briefTitle":421,"status":144,"phases":1469,"primaryCompletion":299,"completion":423,"start":424,"enrollment":425,"conditions":1470,"interventions":1471},[88],[427,428,429,430],[432,433,434,239,435,360,406,436],{"trials":1473,"activeCount":98},[],{"trials":1475,"activeCount":98},[],{"intervention":1477,"totalTrials":686,"cells":1478},"Crizotinib",{"EARLY_PHASE1":1479,"PHASE1":1481,"PHASE2":1483,"PHASE3":1485,"PHASE4":1504,"NA":1506},{"trials":1480,"activeCount":98},[],{"trials":1482,"activeCount":98},[],{"trials":1484,"activeCount":98},[],{"trials":1486,"activeCount":686,"soonestReadout":1491},[1487],{"nctId":1488,"briefTitle":1489,"status":104,"phases":1490,"primaryCompletion":1491,"completion":1491,"start":1492,"enrollment":1493,"conditions":1494,"interventions":1503},"NCT02201992","Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)",[88],"2036-05-01","2015-03-23",166,[1495,1496,1497,1498,1499,1500,1501,1502],"ALK Gene Rearrangement","ALK Gene Translocation","ALK Positive","Stage IB Non-Small Cell Lung Carcinoma AJCC v7","Stage II Non-Small Cell Lung Cancer AJCC v7","Stage IIA Non-Small Cell Lung Carcinoma AJCC v7","Stage IIB Non-Small Cell Lung Carcinoma AJCC v7","Stage IIIA Non-Small Cell Lung Cancer AJCC v7",[1477],{"trials":1505,"activeCount":98},[],{"trials":1507,"activeCount":98},[],{"intervention":685,"totalTrials":686,"cells":1509},{"EARLY_PHASE1":1510,"PHASE1":1512,"PHASE2":1514,"PHASE3":1516,"PHASE4":1522,"NA":1524},{"trials":1511,"activeCount":98},[],{"trials":1513,"activeCount":98},[],{"trials":1515,"activeCount":98},[],{"trials":1517,"activeCount":686,"soonestReadout":678},[1518],{"nctId":675,"briefTitle":676,"status":104,"phases":1519,"primaryCompletion":678,"completion":679,"start":680,"enrollment":681,"conditions":1520,"interventions":1521},[88],[683],[219,64,685],{"trials":1523,"activeCount":98},[],{"trials":1525,"activeCount":98},[],{"intervention":747,"totalTrials":686,"cells":1527},{"EARLY_PHASE1":1528,"PHASE1":1530,"PHASE2":1532,"PHASE3":1534,"PHASE4":1540,"NA":1542},{"trials":1529,"activeCount":98},[],{"trials":1531,"activeCount":98},[],{"trials":1533,"activeCount":98},[],{"trials":1535,"activeCount":686,"soonestReadout":157},[1536],{"nctId":739,"briefTitle":740,"status":144,"phases":1537,"primaryCompletion":157,"completion":157,"start":300,"enrollment":742,"conditions":1538,"interventions":1539},[88],[723,744,745],[725,747,727,692],{"trials":1541,"activeCount":98},[],{"trials":1543,"activeCount":98},[],{"intervention":1192,"totalTrials":686,"cells":1545},{"EARLY_PHASE1":1546,"PHASE1":1548,"PHASE2":1550,"PHASE3":1552,"PHASE4":1558,"NA":1560},{"trials":1547,"activeCount":98},[],{"trials":1549,"activeCount":98},[],{"trials":1551,"activeCount":98},[],{"trials":1553,"activeCount":686,"soonestReadout":779},[1554],{"nctId":1185,"briefTitle":1186,"status":104,"phases":1555,"primaryCompletion":779,"completion":779,"start":1188,"enrollment":1189,"conditions":1556,"interventions":1557},[88],[1164],[1170,1192],{"trials":1559,"activeCount":98},[],{"trials":1561,"activeCount":98},[],{"intervention":39,"totalTrials":686,"cells":1563},{"EARLY_PHASE1":1564,"PHASE1":1566,"PHASE2":1568,"PHASE3":1570,"PHASE4":1578,"NA":1580},{"trials":1565,"activeCount":98},[],{"trials":1567,"activeCount":98},[],{"trials":1569,"activeCount":98},[],{"trials":1571,"activeCount":686,"soonestReadout":38},[1572],{"nctId":36,"briefTitle":37,"status":104,"phases":1573,"primaryCompletion":38,"completion":106,"start":1574,"enrollment":1575,"conditions":1576,"interventions":1577},[88],"1999-03-25",1150,[22],[39],{"trials":1579,"activeCount":98},[],{"trials":1581,"activeCount":98},[],{"intervention":450,"totalTrials":456,"cells":1583},{"EARLY_PHASE1":1584,"PHASE1":1586,"PHASE2":1588,"PHASE3":1594,"PHASE4":1608,"NA":1610},{"trials":1585,"activeCount":98},[],{"trials":1587,"activeCount":98},[],{"trials":1589,"activeCount":98},[1590],{"nctId":526,"briefTitle":527,"status":181,"phases":1591,"primaryCompletion":529,"completion":530,"start":531,"enrollment":320,"conditions":1592,"interventions":1593},[87],[14],[450,534,115,535,204],{"trials":1595,"activeCount":686,"soonestReadout":299},[1596,1600,1604],{"nctId":559,"briefTitle":560,"status":181,"phases":1597,"primaryCompletion":562,"completion":184,"start":563,"enrollment":564,"conditions":1598,"interventions":1599},[88],[14],[240,138,432,567],{"nctId":420,"briefTitle":421,"status":144,"phases":1601,"primaryCompletion":299,"completion":423,"start":424,"enrollment":425,"conditions":1602,"interventions":1603},[88],[427,428,429,430],[432,433,434,239,435,360,406,436],{"nctId":438,"briefTitle":439,"status":410,"phases":1605,"primaryCompletion":413,"completion":441,"start":442,"enrollment":443,"conditions":1606,"interventions":1607},[88],[445,446,447],[449,191,203,450],{"trials":1609,"activeCount":98},[],{"trials":1611,"activeCount":98},[1612,1616],{"nctId":573,"briefTitle":574,"status":181,"phases":1613,"primaryCompletion":576,"completion":576,"start":577,"enrollment":578,"conditions":1614,"interventions":1615},[],[14],[450,115,204,581],{"nctId":583,"briefTitle":584,"status":181,"phases":1617,"primaryCompletion":586,"completion":586,"start":587,"enrollment":588,"conditions":1618,"interventions":1619},[],[14],[450,115,204,324,591,592],{"intervention":190,"totalTrials":33,"cells":1621},{"EARLY_PHASE1":1622,"PHASE1":1624,"PHASE2":1626,"PHASE3":1632,"PHASE4":1638,"NA":1640},{"trials":1623,"activeCount":98},[],{"trials":1625,"activeCount":98},[],{"trials":1627,"activeCount":98},[1628],{"nctId":179,"briefTitle":180,"status":181,"phases":1629,"primaryCompletion":183,"completion":184,"start":185,"enrollment":186,"conditions":1630,"interventions":1631},[87],[188],[190,44,191],{"trials":1633,"activeCount":686,"soonestReadout":299},[1634],{"nctId":420,"briefTitle":421,"status":144,"phases":1635,"primaryCompletion":299,"completion":423,"start":424,"enrollment":425,"conditions":1636,"interventions":1637},[88],[427,428,429,430],[432,433,434,239,435,360,406,436],{"trials":1639,"activeCount":98},[],{"trials":1641,"activeCount":98},[1642],{"nctId":315,"briefTitle":316,"status":181,"phases":1643,"primaryCompletion":318,"completion":318,"start":319,"enrollment":320,"conditions":1644,"interventions":1645},[],[25],[190,44,323,324,325],{"intervention":54,"totalTrials":376,"cells":1647},{"EARLY_PHASE1":1648,"PHASE1":1650,"PHASE2":1652,"PHASE3":1662,"PHASE4":1664,"NA":1666},{"trials":1649,"activeCount":98},[],{"trials":1651,"activeCount":98},[],{"trials":1653,"activeCount":376,"soonestReadout":53},[1654,1658],{"nctId":51,"briefTitle":52,"status":104,"phases":1655,"primaryCompletion":53,"completion":106,"start":470,"enrollment":471,"conditions":1656,"interventions":1657},[87],[473,474,475,476,477,478,479],[54,481],{"nctId":71,"briefTitle":72,"status":104,"phases":1659,"primaryCompletion":73,"completion":130,"start":131,"enrollment":132,"conditions":1660,"interventions":1661},[87],[134,135,136],[49,138,93,139,140],{"trials":1663,"activeCount":98},[],{"trials":1665,"activeCount":98},[],{"trials":1667,"activeCount":98},[],{"intervention":363,"totalTrials":376,"cells":1669},{"EARLY_PHASE1":1670,"PHASE1":1672,"PHASE2":1674,"PHASE3":1684,"PHASE4":1686,"NA":1688},{"trials":1671,"activeCount":98},[],{"trials":1673,"activeCount":98},[],{"trials":1675,"activeCount":376,"soonestReadout":82},[1676,1680],{"nctId":350,"briefTitle":351,"status":104,"phases":1677,"primaryCompletion":82,"completion":353,"start":354,"enrollment":355,"conditions":1678,"interventions":1679},[87],[357,358],[239,219,126,360,361,362,363],{"nctId":636,"briefTitle":637,"status":104,"phases":1681,"primaryCompletion":639,"completion":640,"start":641,"enrollment":642,"conditions":1682,"interventions":1683},[87],[32,610,611,613,30,619,620,621,623],[64,363,240,645,646,647],{"trials":1685,"activeCount":98},[],{"trials":1687,"activeCount":98},[],{"trials":1689,"activeCount":98},[],{"intervention":1169,"totalTrials":376,"cells":1691},{"EARLY_PHASE1":1692,"PHASE1":1694,"PHASE2":1696,"PHASE3":1702,"PHASE4":1734,"NA":1736},{"trials":1693,"activeCount":98},[],{"trials":1695,"activeCount":98},[],{"trials":1697,"activeCount":686,"soonestReadout":353},[1698],{"nctId":1157,"briefTitle":1158,"status":104,"phases":1699,"primaryCompletion":353,"completion":353,"start":1160,"enrollment":1161,"conditions":1700,"interventions":1701},[87],[1163,1164],[1166,1167,1168,1169,1170],{"trials":1703,"activeCount":98},[1704],{"nctId":1705,"briefTitle":1706,"status":181,"phases":1707,"primaryCompletion":1708,"completion":1709,"start":1710,"enrollment":1711,"conditions":1712,"interventions":1730},"NCT02085408","Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia",[88],"2021-02-22","2022-12-21","2011-02-04",727,[1713,1714,1715,1716,1717,1718,1719,1720,1721,1722,1723,1724,1725,1726,1727,1728,1729],"Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome","Adult Acute Megakaryoblastic Leukemia (M7)","Adult Acute Minimally Differentiated Myeloid Leukemia (M0)","Adult Acute Monoblastic Leukemia (M5a)","Adult Acute Monocytic Leukemia (M5b)","Adult Acute Myeloblastic Leukemia With Maturation (M2)","Adult Acute Myeloblastic Leukemia Without Maturation (M1)","Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities","Adult Acute Myeloid Leukemia With Del(5q)","Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)","Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)","Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)","Adult Acute Myelomonocytic Leukemia (M4)","Adult Erythroleukemia (M6a)","Adult Pure Erythroid Leukemia (M6b)","Secondary Acute Myeloid Leukemia","Untreated Adult Acute Myeloid Leukemia",[1731,1169,1732,1733],"Daunorubicin","Clofarabine","Decitabine",{"trials":1735,"activeCount":98},[],{"trials":1737,"activeCount":98},[],{"intervention":1739,"totalTrials":33,"cells":1740},"Prednisone",{"EARLY_PHASE1":1741,"PHASE1":1743,"PHASE2":1745,"PHASE3":1789,"PHASE4":1791,"NA":1793},{"trials":1742,"activeCount":98},[],{"trials":1744,"activeCount":98},[],{"trials":1746,"activeCount":686,"soonestReadout":68},[1747,1761,1775],{"nctId":1748,"briefTitle":1749,"status":410,"phases":1750,"primaryCompletion":1751,"completion":1751,"start":1752,"enrollment":686,"conditions":1753,"interventions":1757},"NCT04438382","Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis",[87],"2023-12-21","2021-01-07",[1754,1755,1756],"Hematopoietic and Lymphoid Cell Neoplasm","Malignant Solid Neoplasm","Steroid-Refractory Pneumonitis",[1758,1759,1739,1760],"Infliximab","Intravenous Immunoglobulin Therapy","Methylprednisolone",{"nctId":66,"briefTitle":67,"status":104,"phases":1762,"primaryCompletion":68,"completion":1763,"start":1764,"enrollment":1765,"conditions":1766,"interventions":1772},[87],"2026-04-01","2018-04-26",223,[1767,1768,1769,1770,1771],"Castration Levels of Testosterone","Castration-Resistant Prostate Carcinoma","Metastatic Prostate Carcinoma in the Soft Tissue","Prostate Carcinoma Metastatic in the Bone","Stage IV Prostate Adenocarcinoma AJCC v7",[69,1773,1774,1739],"Androgen deprivation therapy","Cabazitaxel",{"nctId":1776,"briefTitle":1777,"status":410,"phases":1778,"primaryCompletion":1779,"completion":1780,"start":1781,"enrollment":456,"conditions":1782,"interventions":1783},"NCT01390584","Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma",[87],"2015-04-09","2018-05-18","2013-05-24",[20],[218,1784,217,1785,139,1786,1787,1788,1739],"Bleomycin","Dacarbazine","Cyclophosphamide","Vincristine","Procarbazine",{"trials":1790,"activeCount":98},[],{"trials":1792,"activeCount":98},[],{"trials":1794,"activeCount":98},[],{"intervention":139,"totalTrials":376,"cells":1796},{"EARLY_PHASE1":1797,"PHASE1":1799,"PHASE2":1801,"PHASE3":1811,"PHASE4":1813,"NA":1815},{"trials":1798,"activeCount":98},[],{"trials":1800,"activeCount":98},[],{"trials":1802,"activeCount":686,"soonestReadout":73},[1803,1807],{"nctId":71,"briefTitle":72,"status":104,"phases":1804,"primaryCompletion":73,"completion":130,"start":131,"enrollment":132,"conditions":1805,"interventions":1806},[87],[134,135,136],[49,138,93,139,140],{"nctId":1776,"briefTitle":1777,"status":410,"phases":1808,"primaryCompletion":1779,"completion":1780,"start":1781,"enrollment":456,"conditions":1809,"interventions":1810},[87],[20],[218,1784,217,1785,139,1786,1787,1788,1739],{"trials":1812,"activeCount":98},[],{"trials":1814,"activeCount":98},[],{"trials":1816,"activeCount":98},[],{"intervention":1818,"totalTrials":686,"cells":1819},"Chemotherapy",{"EARLY_PHASE1":1820,"PHASE1":1822,"PHASE2":1824,"PHASE3":1836,"PHASE4":1838,"NA":1840},{"trials":1821,"activeCount":98},[],{"trials":1823,"activeCount":98},[],{"trials":1825,"activeCount":686,"soonestReadout":1830},[1826],{"nctId":1827,"briefTitle":1828,"status":104,"phases":1829,"primaryCompletion":1830,"completion":339,"start":1831,"enrollment":1832,"conditions":1833,"interventions":1835},"NCT05710328","Testing the Role of FDG-PET\u002FCT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial",[87],"2027-05-31","2023-05-10",235,[32,612,1834,30],"HER2-Positive Breast Carcinoma",[1818],{"trials":1837,"activeCount":98},[],{"trials":1839,"activeCount":98},[],{"trials":1841,"activeCount":98},[],{"intervention":69,"totalTrials":686,"cells":1843},{"EARLY_PHASE1":1844,"PHASE1":1846,"PHASE2":1848,"PHASE3":1854,"PHASE4":1856,"NA":1858},{"trials":1845,"activeCount":98},[],{"trials":1847,"activeCount":98},[],{"trials":1849,"activeCount":686,"soonestReadout":68},[1850],{"nctId":66,"briefTitle":67,"status":104,"phases":1851,"primaryCompletion":68,"completion":1763,"start":1764,"enrollment":1765,"conditions":1852,"interventions":1853},[87],[1767,1768,1769,1770,1771],[69,1773,1774,1739],{"trials":1855,"activeCount":98},[],{"trials":1857,"activeCount":98},[],{"trials":1859,"activeCount":98},[],{"intervention":1773,"totalTrials":686,"cells":1861},{"EARLY_PHASE1":1862,"PHASE1":1864,"PHASE2":1866,"PHASE3":1872,"PHASE4":1874,"NA":1876},{"trials":1863,"activeCount":98},[],{"trials":1865,"activeCount":98},[],{"trials":1867,"activeCount":686,"soonestReadout":68},[1868],{"nctId":66,"briefTitle":67,"status":104,"phases":1869,"primaryCompletion":68,"completion":1763,"start":1764,"enrollment":1765,"conditions":1870,"interventions":1871},[87],[1767,1768,1769,1770,1771],[69,1773,1774,1739],{"trials":1873,"activeCount":98},[],{"trials":1875,"activeCount":98},[],{"trials":1877,"activeCount":98},[],{"intervention":1774,"totalTrials":686,"cells":1879},{"EARLY_PHASE1":1880,"PHASE1":1882,"PHASE2":1884,"PHASE3":1890,"PHASE4":1892,"NA":1894},{"trials":1881,"activeCount":98},[],{"trials":1883,"activeCount":98},[],{"trials":1885,"activeCount":686,"soonestReadout":68},[1886],{"nctId":66,"briefTitle":67,"status":104,"phases":1887,"primaryCompletion":68,"completion":1763,"start":1764,"enrollment":1765,"conditions":1888,"interventions":1889},[87],[1767,1768,1769,1770,1771],[69,1773,1774,1739],{"trials":1891,"activeCount":98},[],{"trials":1893,"activeCount":98},[],{"trials":1895,"activeCount":98},[],{"intervention":1897,"totalTrials":686,"cells":1898},"Sinecatechins",{"EARLY_PHASE1":1899,"PHASE1":1901,"PHASE2":1903,"PHASE3":1912,"PHASE4":1914,"NA":1916},{"trials":1900,"activeCount":98},[],{"trials":1902,"activeCount":98},[],{"trials":1904,"activeCount":686,"soonestReadout":1084},[1905],{"nctId":1906,"briefTitle":1907,"status":104,"phases":1908,"primaryCompletion":1084,"completion":1084,"start":1909,"enrollment":1161,"conditions":1910,"interventions":1911},"NCT04597359","To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring",[87],"2021-10-05",[1076],[1897],{"trials":1913,"activeCount":98},[],{"trials":1915,"activeCount":98},[],{"trials":1917,"activeCount":98},[],{"intervention":348,"totalTrials":686,"cells":1919},{"EARLY_PHASE1":1920,"PHASE1":1922,"PHASE2":1924,"PHASE3":1930,"PHASE4":1932,"NA":1934},{"trials":1921,"activeCount":98},[],{"trials":1923,"activeCount":98},[],{"trials":1925,"activeCount":686,"soonestReadout":339},[1926],{"nctId":336,"briefTitle":337,"status":104,"phases":1927,"primaryCompletion":339,"completion":339,"start":340,"enrollment":341,"conditions":1928,"interventions":1929},[87],[231,232,343,344,345,346],[49,239,348],{"trials":1931,"activeCount":98},[],{"trials":1933,"activeCount":98},[],{"trials":1935,"activeCount":98},[],{"intervention":362,"totalTrials":686,"cells":1937},{"EARLY_PHASE1":1938,"PHASE1":1940,"PHASE2":1942,"PHASE3":1948,"PHASE4":1950,"NA":1952},{"trials":1939,"activeCount":98},[],{"trials":1941,"activeCount":98},[],{"trials":1943,"activeCount":686,"soonestReadout":82},[1944],{"nctId":350,"briefTitle":351,"status":104,"phases":1945,"primaryCompletion":82,"completion":353,"start":354,"enrollment":355,"conditions":1946,"interventions":1947},[87],[357,358],[239,219,126,360,361,362,363],{"trials":1949,"activeCount":98},[],{"trials":1951,"activeCount":98},[],{"trials":1953,"activeCount":98},[],{"intervention":1166,"totalTrials":686,"cells":1955},{"EARLY_PHASE1":1956,"PHASE1":1958,"PHASE2":1960,"PHASE3":1966,"PHASE4":1968,"NA":1970},{"trials":1957,"activeCount":98},[],{"trials":1959,"activeCount":98},[],{"trials":1961,"activeCount":686,"soonestReadout":353},[1962],{"nctId":1157,"briefTitle":1158,"status":104,"phases":1963,"primaryCompletion":353,"completion":353,"start":1160,"enrollment":1161,"conditions":1964,"interventions":1965},[87],[1163,1164],[1166,1167,1168,1169,1170],{"trials":1967,"activeCount":98},[],{"trials":1969,"activeCount":98},[],{"trials":1971,"activeCount":98},[],{"intervention":1167,"totalTrials":686,"cells":1973},{"EARLY_PHASE1":1974,"PHASE1":1976,"PHASE2":1978,"PHASE3":1984,"PHASE4":1986,"NA":1988},{"trials":1975,"activeCount":98},[],{"trials":1977,"activeCount":98},[],{"trials":1979,"activeCount":686,"soonestReadout":353},[1980],{"nctId":1157,"briefTitle":1158,"status":104,"phases":1981,"primaryCompletion":353,"completion":353,"start":1160,"enrollment":1161,"conditions":1982,"interventions":1983},[87],[1163,1164],[1166,1167,1168,1169,1170],{"trials":1985,"activeCount":98},[],{"trials":1987,"activeCount":98},[],{"trials":1989,"activeCount":98},[],{"intervention":1168,"totalTrials":686,"cells":1991},{"EARLY_PHASE1":1992,"PHASE1":1994,"PHASE2":1996,"PHASE3":2002,"PHASE4":2004,"NA":2006},{"trials":1993,"activeCount":98},[],{"trials":1995,"activeCount":98},[],{"trials":1997,"activeCount":686,"soonestReadout":353},[1998],{"nctId":1157,"briefTitle":1158,"status":104,"phases":1999,"primaryCompletion":353,"completion":353,"start":1160,"enrollment":1161,"conditions":2000,"interventions":2001},[87],[1163,1164],[1166,1167,1168,1169,1170],{"trials":2003,"activeCount":98},[],{"trials":2005,"activeCount":98},[],{"trials":2007,"activeCount":98},[],{"intervention":772,"totalTrials":686,"cells":2009},{"EARLY_PHASE1":2010,"PHASE1":2012,"PHASE2":2014,"PHASE3":2020,"PHASE4":2022,"NA":2024},{"trials":2011,"activeCount":98},[],{"trials":2013,"activeCount":98},[],{"trials":2015,"activeCount":686,"soonestReadout":764},[2016],{"nctId":761,"briefTitle":762,"status":104,"phases":2017,"primaryCompletion":764,"completion":765,"start":766,"enrollment":767,"conditions":2018,"interventions":2019},[87],[769,770],[772,773,774,275],{"trials":2021,"activeCount":98},[],{"trials":2023,"activeCount":98},[],{"trials":2025,"activeCount":98},[],{"intervention":773,"totalTrials":686,"cells":2027},{"EARLY_PHASE1":2028,"PHASE1":2030,"PHASE2":2032,"PHASE3":2038,"PHASE4":2040,"NA":2042},{"trials":2029,"activeCount":98},[],{"trials":2031,"activeCount":98},[],{"trials":2033,"activeCount":686,"soonestReadout":764},[2034],{"nctId":761,"briefTitle":762,"status":104,"phases":2035,"primaryCompletion":764,"completion":765,"start":766,"enrollment":767,"conditions":2036,"interventions":2037},[87],[769,770],[772,773,774,275],{"trials":2039,"activeCount":98},[],{"trials":2041,"activeCount":98},[],{"trials":2043,"activeCount":98},[],{"intervention":774,"totalTrials":686,"cells":2045},{"EARLY_PHASE1":2046,"PHASE1":2048,"PHASE2":2050,"PHASE3":2056,"PHASE4":2058,"NA":2060},{"trials":2047,"activeCount":98},[],{"trials":2049,"activeCount":98},[],{"trials":2051,"activeCount":686,"soonestReadout":764},[2052],{"nctId":761,"briefTitle":762,"status":104,"phases":2053,"primaryCompletion":764,"completion":765,"start":766,"enrollment":767,"conditions":2054,"interventions":2055},[87],[769,770],[772,773,774,275],{"trials":2057,"activeCount":98},[],{"trials":2059,"activeCount":98},[],{"trials":2061,"activeCount":98},[],{"intervention":796,"totalTrials":686,"cells":2063},{"EARLY_PHASE1":2064,"PHASE1":2066,"PHASE2":2068,"PHASE3":2074,"PHASE4":2076,"NA":2078},{"trials":2065,"activeCount":98},[],{"trials":2067,"activeCount":98},[],{"trials":2069,"activeCount":686,"soonestReadout":779},[2070],{"nctId":776,"briefTitle":777,"status":104,"phases":2071,"primaryCompletion":779,"completion":780,"start":781,"enrollment":782,"conditions":2072,"interventions":2073},[87],[784,785,786,787,788,789,790,791,792,793,794],[796,797,275],{"trials":2075,"activeCount":98},[],{"trials":2077,"activeCount":98},[],{"trials":2079,"activeCount":98},[],{"intervention":797,"totalTrials":686,"cells":2081},{"EARLY_PHASE1":2082,"PHASE1":2084,"PHASE2":2086,"PHASE3":2092,"PHASE4":2094,"NA":2096},{"trials":2083,"activeCount":98},[],{"trials":2085,"activeCount":98},[],{"trials":2087,"activeCount":686,"soonestReadout":779},[2088],{"nctId":776,"briefTitle":777,"status":104,"phases":2089,"primaryCompletion":779,"completion":780,"start":781,"enrollment":782,"conditions":2090,"interventions":2091},[87],[784,785,786,787,788,789,790,791,792,793,794],[796,797,275],{"trials":2093,"activeCount":98},[],{"trials":2095,"activeCount":98},[],{"trials":2097,"activeCount":98},[],{"intervention":2099,"totalTrials":686,"cells":2100},"Gadolinium-Chelate",{"EARLY_PHASE1":2101,"PHASE1":2103,"PHASE2":2105,"PHASE3":2116,"PHASE4":2118,"NA":2120},{"trials":2102,"activeCount":98},[],{"trials":2104,"activeCount":98},[],{"trials":2106,"activeCount":686,"soonestReadout":1830},[2107],{"nctId":2108,"briefTitle":2109,"status":144,"phases":2110,"primaryCompletion":1830,"completion":1830,"start":2111,"enrollment":2112,"conditions":2113,"interventions":2115},"NCT06319027","Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial",[87],"2024-04-11",100,[2114],"Glioblastoma, IDH-Wildtype",[2099],{"trials":2117,"activeCount":98},[],{"trials":2119,"activeCount":98},[],{"trials":2121,"activeCount":98},[],{"intervention":645,"totalTrials":686,"cells":2123},{"EARLY_PHASE1":2124,"PHASE1":2126,"PHASE2":2128,"PHASE3":2134,"PHASE4":2136,"NA":2138},{"trials":2125,"activeCount":98},[],{"trials":2127,"activeCount":98},[],{"trials":2129,"activeCount":686,"soonestReadout":639},[2130],{"nctId":636,"briefTitle":637,"status":104,"phases":2131,"primaryCompletion":639,"completion":640,"start":641,"enrollment":642,"conditions":2132,"interventions":2133},[87],[32,610,611,613,30,619,620,621,623],[64,363,240,645,646,647],{"trials":2135,"activeCount":98},[],{"trials":2137,"activeCount":98},[],{"trials":2139,"activeCount":98},[],{"intervention":646,"totalTrials":686,"cells":2141},{"EARLY_PHASE1":2142,"PHASE1":2144,"PHASE2":2146,"PHASE3":2152,"PHASE4":2154,"NA":2156},{"trials":2143,"activeCount":98},[],{"trials":2145,"activeCount":98},[],{"trials":2147,"activeCount":686,"soonestReadout":639},[2148],{"nctId":636,"briefTitle":637,"status":104,"phases":2149,"primaryCompletion":639,"completion":640,"start":641,"enrollment":642,"conditions":2150,"interventions":2151},[87],[32,610,611,613,30,619,620,621,623],[64,363,240,645,646,647],{"trials":2153,"activeCount":98},[],{"trials":2155,"activeCount":98},[],{"trials":2157,"activeCount":98},[],{"intervention":647,"totalTrials":686,"cells":2159},{"EARLY_PHASE1":2160,"PHASE1":2162,"PHASE2":2164,"PHASE3":2170,"PHASE4":2172,"NA":2174},{"trials":2161,"activeCount":98},[],{"trials":2163,"activeCount":98},[],{"trials":2165,"activeCount":686,"soonestReadout":639},[2166],{"nctId":636,"briefTitle":637,"status":104,"phases":2167,"primaryCompletion":639,"completion":640,"start":641,"enrollment":642,"conditions":2168,"interventions":2169},[87],[32,610,611,613,30,619,620,621,623],[64,363,240,645,646,647],{"trials":2171,"activeCount":98},[],{"trials":2173,"activeCount":98},[],{"trials":2175,"activeCount":98},[],{"intervention":78,"totalTrials":686,"cells":2177},{"EARLY_PHASE1":2178,"PHASE1":2180,"PHASE2":2182,"PHASE3":2201,"PHASE4":2203,"NA":2205},{"trials":2179,"activeCount":98},[],{"trials":2181,"activeCount":98},[],{"trials":2183,"activeCount":686,"soonestReadout":77},[2184],{"nctId":75,"briefTitle":76,"status":104,"phases":2185,"primaryCompletion":77,"completion":2186,"start":2187,"enrollment":767,"conditions":2188,"interventions":2198},[86,87],"2028-12-31","2018-08-13",[2189,2190,2191,2192,2193,2194,2195,2196,2197],"Recurrent Adult Lymphoblastic Lymphoma","Recurrent B Acute Lymphoblastic Leukemia","Recurrent B Lymphoblastic Lymphoma","Recurrent T Acute Lymphoblastic Leukemia","Recurrent T Lymphoblastic Lymphoma","Refractory B Acute Lymphoblastic Leukemia","Refractory B Lymphoblastic Lymphoma","Refractory T Acute Lymphoblastic Leukemia","Refractory T Lymphoblastic Lymphoma",[78,2199,2200],"Vincristine Liposomal","Vincristine Sulfate",{"trials":2202,"activeCount":98},[],{"trials":2204,"activeCount":98},[],{"trials":2206,"activeCount":98},[],{"intervention":2199,"totalTrials":686,"cells":2208},{"EARLY_PHASE1":2209,"PHASE1":2211,"PHASE2":2213,"PHASE3":2219,"PHASE4":2221,"NA":2223},{"trials":2210,"activeCount":98},[],{"trials":2212,"activeCount":98},[],{"trials":2214,"activeCount":686,"soonestReadout":77},[2215],{"nctId":75,"briefTitle":76,"status":104,"phases":2216,"primaryCompletion":77,"completion":2186,"start":2187,"enrollment":767,"conditions":2217,"interventions":2218},[86,87],[2189,2190,2191,2192,2193,2194,2195,2196,2197],[78,2199,2200],{"trials":2220,"activeCount":98},[],{"trials":2222,"activeCount":98},[],{"trials":2224,"activeCount":98},[],{"intervention":2200,"totalTrials":686,"cells":2226},{"EARLY_PHASE1":2227,"PHASE1":2229,"PHASE2":2231,"PHASE3":2237,"PHASE4":2239,"NA":2241},{"trials":2228,"activeCount":98},[],{"trials":2230,"activeCount":98},[],{"trials":2232,"activeCount":686,"soonestReadout":77},[2233],{"nctId":75,"briefTitle":76,"status":104,"phases":2234,"primaryCompletion":77,"completion":2186,"start":2187,"enrollment":767,"conditions":2235,"interventions":2236},[86,87],[2189,2190,2191,2192,2193,2194,2195,2196,2197],[78,2199,2200],{"trials":2238,"activeCount":98},[],{"trials":2240,"activeCount":98},[],{"trials":2242,"activeCount":98},[],{"intervention":59,"totalTrials":686,"cells":2244},{"EARLY_PHASE1":2245,"PHASE1":2247,"PHASE2":2249,"PHASE3":2251,"PHASE4":2253,"NA":2255},{"trials":2246,"activeCount":98},[],{"trials":2248,"activeCount":98},[],{"trials":2250,"activeCount":98},[],{"trials":2252,"activeCount":98},[],{"trials":2254,"activeCount":98},[],{"trials":2256,"activeCount":686,"soonestReadout":58},[2257],{"nctId":56,"briefTitle":57,"status":104,"phases":2258,"primaryCompletion":58,"completion":106,"start":2259,"enrollment":2260,"conditions":2261,"interventions":2268},[90],"2013-06-11",1046,[2262,2263,2264,2265,2266,2267,285,289,290,291],"Estrogen Receptor-positive Breast Cancer","Musculoskeletal Complications","Progesterone Receptor-positive Breast Cancer","Recurrent Breast Cancer","Stage IA Breast Cancer","Stage IB Breast Cancer",[59],{"intervention":2270,"totalTrials":686,"cells":2271},"Endocrine Therapy",{"EARLY_PHASE1":2272,"PHASE1":2274,"PHASE2":2276,"PHASE3":2278,"PHASE4":2280,"NA":2282},{"trials":2273,"activeCount":98},[],{"trials":2275,"activeCount":98},[],{"trials":2277,"activeCount":98},[],{"trials":2279,"activeCount":98},[],{"trials":2281,"activeCount":98},[],{"trials":2283,"activeCount":686,"soonestReadout":2288},[2284],{"nctId":2285,"briefTitle":2286,"status":104,"phases":2287,"primaryCompletion":2288,"completion":2288,"start":2289,"enrollment":2290,"conditions":2291,"interventions":2293},"NCT02352883","MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ",[90],"2027-11","2015-03-25",368,[2292],"Ductal Breast Carcinoma In Situ",[2270],{"intervention":673,"totalTrials":686,"cells":2295},{"EARLY_PHASE1":2296,"PHASE1":2298,"PHASE2":2300,"PHASE3":2302,"PHASE4":2308,"NA":2310},{"trials":2297,"activeCount":98},[],{"trials":2299,"activeCount":98},[],{"trials":2301,"activeCount":98},[],{"trials":2303,"activeCount":98},[2304],{"nctId":663,"briefTitle":664,"status":181,"phases":2305,"primaryCompletion":666,"completion":667,"start":668,"enrollment":669,"conditions":2306,"interventions":2307},[88],[671],[673,658],{"trials":2309,"activeCount":98},[],{"trials":2311,"activeCount":98},[],{"intervention":2313,"totalTrials":686,"cells":2314},"selenium",{"EARLY_PHASE1":2315,"PHASE1":2317,"PHASE2":2319,"PHASE3":2321,"PHASE4":2333,"NA":2335},{"trials":2316,"activeCount":98},[],{"trials":2318,"activeCount":98},[],{"trials":2320,"activeCount":98},[],{"trials":2322,"activeCount":98},[2323],{"nctId":2324,"briefTitle":2325,"status":181,"phases":2326,"primaryCompletion":2327,"completion":2328,"start":2329,"enrollment":2330,"conditions":2331,"interventions":2332},"NCT00008385","Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer",[88],"2011-06","2019-11","2000-12-18",1772,[14],[2313],{"trials":2334,"activeCount":98},[],{"trials":2336,"activeCount":98},[],{"intervention":567,"totalTrials":686,"cells":2338},{"EARLY_PHASE1":2339,"PHASE1":2341,"PHASE2":2343,"PHASE3":2345,"PHASE4":2351,"NA":2353},{"trials":2340,"activeCount":98},[],{"trials":2342,"activeCount":98},[],{"trials":2344,"activeCount":98},[],{"trials":2346,"activeCount":98},[2347],{"nctId":559,"briefTitle":560,"status":181,"phases":2348,"primaryCompletion":562,"completion":184,"start":563,"enrollment":564,"conditions":2349,"interventions":2350},[88],[14],[240,138,432,567],{"trials":2352,"activeCount":98},[],{"trials":2354,"activeCount":98},[],{"intervention":1731,"totalTrials":686,"cells":2356},{"EARLY_PHASE1":2357,"PHASE1":2359,"PHASE2":2361,"PHASE3":2363,"PHASE4":2369,"NA":2371},{"trials":2358,"activeCount":98},[],{"trials":2360,"activeCount":98},[],{"trials":2362,"activeCount":98},[],{"trials":2364,"activeCount":98},[2365],{"nctId":1705,"briefTitle":1706,"status":181,"phases":2366,"primaryCompletion":1708,"completion":1709,"start":1710,"enrollment":1711,"conditions":2367,"interventions":2368},[88],[1713,1714,1715,1716,1717,1718,1719,1720,1721,1722,1723,1724,1725,1726,1727,1728,1729],[1731,1169,1732,1733],{"trials":2370,"activeCount":98},[],{"trials":2372,"activeCount":98},[],{"intervention":1732,"totalTrials":686,"cells":2374},{"EARLY_PHASE1":2375,"PHASE1":2377,"PHASE2":2379,"PHASE3":2381,"PHASE4":2387,"NA":2389},{"trials":2376,"activeCount":98},[],{"trials":2378,"activeCount":98},[],{"trials":2380,"activeCount":98},[],{"trials":2382,"activeCount":98},[2383],{"nctId":1705,"briefTitle":1706,"status":181,"phases":2384,"primaryCompletion":1708,"completion":1709,"start":1710,"enrollment":1711,"conditions":2385,"interventions":2386},[88],[1713,1714,1715,1716,1717,1718,1719,1720,1721,1722,1723,1724,1725,1726,1727,1728,1729],[1731,1169,1732,1733],{"trials":2388,"activeCount":98},[],{"trials":2390,"activeCount":98},[],{"intervention":1733,"totalTrials":686,"cells":2392},{"EARLY_PHASE1":2393,"PHASE1":2395,"PHASE2":2397,"PHASE3":2399,"PHASE4":2405,"NA":2407},{"trials":2394,"activeCount":98},[],{"trials":2396,"activeCount":98},[],{"trials":2398,"activeCount":98},[],{"trials":2400,"activeCount":98},[2401],{"nctId":1705,"briefTitle":1706,"status":181,"phases":2402,"primaryCompletion":1708,"completion":1709,"start":1710,"enrollment":1711,"conditions":2403,"interventions":2404},[88],[1713,1714,1715,1716,1717,1718,1719,1720,1721,1722,1723,1724,1725,1726,1727,1728,1729],[1731,1169,1732,1733],{"trials":2406,"activeCount":98},[],{"trials":2408,"activeCount":98},[],{"intervention":535,"totalTrials":376,"cells":2410},{"EARLY_PHASE1":2411,"PHASE1":2413,"PHASE2":2415,"PHASE3":2425,"PHASE4":2427,"NA":2429},{"trials":2412,"activeCount":98},[],{"trials":2414,"activeCount":98},[],{"trials":2416,"activeCount":98},[2417,2421],{"nctId":526,"briefTitle":527,"status":181,"phases":2418,"primaryCompletion":529,"completion":530,"start":531,"enrollment":320,"conditions":2419,"interventions":2420},[87],[14],[450,534,115,535,204],{"nctId":1776,"briefTitle":1777,"status":410,"phases":2422,"primaryCompletion":1779,"completion":1780,"start":1781,"enrollment":456,"conditions":2423,"interventions":2424},[87],[20],[218,1784,217,1785,139,1786,1787,1788,1739],{"trials":2426,"activeCount":98},[],{"trials":2428,"activeCount":98},[],{"trials":2430,"activeCount":98},[],{"intervention":218,"totalTrials":376,"cells":2432},{"EARLY_PHASE1":2433,"PHASE1":2435,"PHASE2":2437,"PHASE3":2447,"PHASE4":2449,"NA":2451},{"trials":2434,"activeCount":98},[],{"trials":2436,"activeCount":98},[],{"trials":2438,"activeCount":98},[2439,2443],{"nctId":1776,"briefTitle":1777,"status":410,"phases":2440,"primaryCompletion":1779,"completion":1780,"start":1781,"enrollment":456,"conditions":2441,"interventions":2442},[87],[20],[218,1784,217,1785,139,1786,1787,1788,1739],{"nctId":206,"briefTitle":207,"status":181,"phases":2444,"primaryCompletion":209,"completion":210,"start":211,"enrollment":212,"conditions":2445,"interventions":2446},[87],[214],[216,217,218,93,219,138,220],{"trials":2448,"activeCount":98},[],{"trials":2450,"activeCount":98},[],{"trials":2452,"activeCount":98},[],{"intervention":217,"totalTrials":376,"cells":2454},{"EARLY_PHASE1":2455,"PHASE1":2457,"PHASE2":2459,"PHASE3":2469,"PHASE4":2471,"NA":2473},{"trials":2456,"activeCount":98},[],{"trials":2458,"activeCount":98},[],{"trials":2460,"activeCount":98},[2461,2465],{"nctId":1776,"briefTitle":1777,"status":410,"phases":2462,"primaryCompletion":1779,"completion":1780,"start":1781,"enrollment":456,"conditions":2463,"interventions":2464},[87],[20],[218,1784,217,1785,139,1786,1787,1788,1739],{"nctId":206,"briefTitle":207,"status":181,"phases":2466,"primaryCompletion":209,"completion":210,"start":211,"enrollment":212,"conditions":2467,"interventions":2468},[87],[214],[216,217,218,93,219,138,220],{"trials":2470,"activeCount":98},[],{"trials":2472,"activeCount":98},[],{"trials":2474,"activeCount":98},[],{"intervention":1758,"totalTrials":686,"cells":2476},{"EARLY_PHASE1":2477,"PHASE1":2479,"PHASE2":2481,"PHASE3":2487,"PHASE4":2489,"NA":2491},{"trials":2478,"activeCount":98},[],{"trials":2480,"activeCount":98},[],{"trials":2482,"activeCount":98},[2483],{"nctId":1748,"briefTitle":1749,"status":410,"phases":2484,"primaryCompletion":1751,"completion":1751,"start":1752,"enrollment":686,"conditions":2485,"interventions":2486},[87],[1754,1755,1756],[1758,1759,1739,1760],{"trials":2488,"activeCount":98},[],{"trials":2490,"activeCount":98},[],{"trials":2492,"activeCount":98},[],{"intervention":1759,"totalTrials":686,"cells":2494},{"EARLY_PHASE1":2495,"PHASE1":2497,"PHASE2":2499,"PHASE3":2505,"PHASE4":2507,"NA":2509},{"trials":2496,"activeCount":98},[],{"trials":2498,"activeCount":98},[],{"trials":2500,"activeCount":98},[2501],{"nctId":1748,"briefTitle":1749,"status":410,"phases":2502,"primaryCompletion":1751,"completion":1751,"start":1752,"enrollment":686,"conditions":2503,"interventions":2504},[87],[1754,1755,1756],[1758,1759,1739,1760],{"trials":2506,"activeCount":98},[],{"trials":2508,"activeCount":98},[],{"trials":2510,"activeCount":98},[],{"intervention":1760,"totalTrials":686,"cells":2512},{"EARLY_PHASE1":2513,"PHASE1":2515,"PHASE2":2517,"PHASE3":2523,"PHASE4":2525,"NA":2527},{"trials":2514,"activeCount":98},[],{"trials":2516,"activeCount":98},[],{"trials":2518,"activeCount":98},[2519],{"nctId":1748,"briefTitle":1749,"status":410,"phases":2520,"primaryCompletion":1751,"completion":1751,"start":1752,"enrollment":686,"conditions":2521,"interventions":2522},[87],[1754,1755,1756],[1758,1759,1739,1760],{"trials":2524,"activeCount":98},[],{"trials":2526,"activeCount":98},[],{"trials":2528,"activeCount":98},[],{"intervention":2530,"totalTrials":686,"cells":2531},"Depsipeptide",{"EARLY_PHASE1":2532,"PHASE1":2534,"PHASE2":2536,"PHASE3":2549,"PHASE4":2551,"NA":2553},{"trials":2533,"activeCount":98},[],{"trials":2535,"activeCount":98},[],{"trials":2537,"activeCount":98},[2538],{"nctId":2539,"briefTitle":2540,"status":410,"phases":2541,"primaryCompletion":2542,"completion":2543,"start":2544,"enrollment":28,"conditions":2545,"interventions":2548},"NCT00104884","FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma",[87],"2006-05","2009-03","2005-10-04",[2546,2547],"Malignant Melanoma","Melanoma",[2530],{"trials":2550,"activeCount":98},[],{"trials":2552,"activeCount":98},[],{"trials":2554,"activeCount":98},[],{"intervention":710,"totalTrials":686,"cells":2556},{"EARLY_PHASE1":2557,"PHASE1":2559,"PHASE2":2561,"PHASE3":2567,"PHASE4":2569,"NA":2571},{"trials":2558,"activeCount":98},[],{"trials":2560,"activeCount":98},[],{"trials":2562,"activeCount":98},[2563],{"nctId":701,"briefTitle":702,"status":181,"phases":2564,"primaryCompletion":704,"completion":704,"start":705,"enrollment":706,"conditions":2565,"interventions":2566},[87],[20],[709,710,711,712],{"trials":2568,"activeCount":98},[],{"trials":2570,"activeCount":98},[],{"trials":2572,"activeCount":98},[],{"intervention":2574,"totalTrials":686,"cells":2575},"afatinib",{"EARLY_PHASE1":2576,"PHASE1":2578,"PHASE2":2580,"PHASE3":2591,"PHASE4":2593,"NA":2595},{"trials":2577,"activeCount":98},[],{"trials":2579,"activeCount":98},[],{"trials":2581,"activeCount":98},[2582],{"nctId":2583,"briefTitle":2584,"status":410,"phases":2585,"primaryCompletion":2586,"completion":2587,"start":2588,"enrollment":33,"conditions":2589,"interventions":2590},"NCT01824823","Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence",[87],"2015-12-13","2020-12","2014-06-30",[161],[2574],{"trials":2592,"activeCount":98},[],{"trials":2594,"activeCount":98},[],{"trials":2596,"activeCount":98},[],{"intervention":2598,"totalTrials":686,"cells":2599},"Dabrafenib mesylate",{"EARLY_PHASE1":2600,"PHASE1":2602,"PHASE2":2604,"PHASE3":2616,"PHASE4":2618,"NA":2620},{"trials":2601,"activeCount":98},[],{"trials":2603,"activeCount":98},[],{"trials":2605,"activeCount":98},[2606],{"nctId":2607,"briefTitle":2608,"status":410,"phases":2609,"primaryCompletion":68,"completion":68,"start":2610,"enrollment":23,"conditions":2611,"interventions":2613},"NCT04527549","Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E\u002FK Melanoma",[87],"2021-06-01",[786,2612,789,791,793],"Locally Advanced Melanoma",[2598,2614,2615],"Hydroxychloroquine","Trametinib dimethyl sulfoxide",{"trials":2617,"activeCount":98},[],{"trials":2619,"activeCount":98},[],{"trials":2621,"activeCount":98},[],{"intervention":2614,"totalTrials":686,"cells":2623},{"EARLY_PHASE1":2624,"PHASE1":2626,"PHASE2":2628,"PHASE3":2634,"PHASE4":2636,"NA":2638},{"trials":2625,"activeCount":98},[],{"trials":2627,"activeCount":98},[],{"trials":2629,"activeCount":98},[2630],{"nctId":2607,"briefTitle":2608,"status":410,"phases":2631,"primaryCompletion":68,"completion":68,"start":2610,"enrollment":23,"conditions":2632,"interventions":2633},[87],[786,2612,789,791,793],[2598,2614,2615],{"trials":2635,"activeCount":98},[],{"trials":2637,"activeCount":98},[],{"trials":2639,"activeCount":98},[],{"intervention":2615,"totalTrials":686,"cells":2641},{"EARLY_PHASE1":2642,"PHASE1":2644,"PHASE2":2646,"PHASE3":2652,"PHASE4":2654,"NA":2656},{"trials":2643,"activeCount":98},[],{"trials":2645,"activeCount":98},[],{"trials":2647,"activeCount":98},[2648],{"nctId":2607,"briefTitle":2608,"status":410,"phases":2649,"primaryCompletion":68,"completion":68,"start":2610,"enrollment":23,"conditions":2650,"interventions":2651},[87],[786,2612,789,791,793],[2598,2614,2615],{"trials":2653,"activeCount":98},[],{"trials":2655,"activeCount":98},[],{"trials":2657,"activeCount":98},[],{"intervention":127,"totalTrials":686,"cells":2659},{"EARLY_PHASE1":2660,"PHASE1":2662,"PHASE2":2664,"PHASE3":2670,"PHASE4":2672,"NA":2674},{"trials":2661,"activeCount":98},[],{"trials":2663,"activeCount":98},[],{"trials":2665,"activeCount":98},[2666],{"nctId":117,"briefTitle":118,"status":119,"phases":2667,"primaryCompletion":121,"completion":121,"start":122,"enrollment":98,"conditions":2668,"interventions":2669},[87],[124],[93,64,126,127],{"trials":2671,"activeCount":98},[],{"trials":2673,"activeCount":98},[],{"trials":2675,"activeCount":98},[],{"intervention":1181,"totalTrials":686,"cells":2677},{"EARLY_PHASE1":2678,"PHASE1":2680,"PHASE2":2682,"PHASE3":2688,"PHASE4":2690,"NA":2692},{"trials":2679,"activeCount":98},[],{"trials":2681,"activeCount":98},[],{"trials":2683,"activeCount":98},[2684],{"nctId":1172,"briefTitle":1173,"status":410,"phases":2685,"primaryCompletion":1175,"completion":1175,"start":1176,"enrollment":1177,"conditions":2686,"interventions":2687},[87],[1179],[1181,709],{"trials":2689,"activeCount":98},[],{"trials":2691,"activeCount":98},[],{"trials":2693,"activeCount":98},[],{"intervention":967,"totalTrials":686,"cells":2695},{"EARLY_PHASE1":2696,"PHASE1":2698,"PHASE2":2700,"PHASE3":2706,"PHASE4":2708,"NA":2710},{"trials":2697,"activeCount":98},[],{"trials":2699,"activeCount":98},[],{"trials":2701,"activeCount":98},[2702],{"nctId":957,"briefTitle":958,"status":181,"phases":2703,"primaryCompletion":960,"completion":961,"start":962,"enrollment":963,"conditions":2704,"interventions":2705},[87],[965],[219,967],{"trials":2707,"activeCount":98},[],{"trials":2709,"activeCount":98},[],{"trials":2711,"activeCount":98},[],{"intervention":534,"totalTrials":686,"cells":2713},{"EARLY_PHASE1":2714,"PHASE1":2716,"PHASE2":2718,"PHASE3":2724,"PHASE4":2726,"NA":2728},{"trials":2715,"activeCount":98},[],{"trials":2717,"activeCount":98},[],{"trials":2719,"activeCount":98},[2720],{"nctId":526,"briefTitle":527,"status":181,"phases":2721,"primaryCompletion":529,"completion":530,"start":531,"enrollment":320,"conditions":2722,"interventions":2723},[87],[14],[450,534,115,535,204],{"trials":2725,"activeCount":98},[],{"trials":2727,"activeCount":98},[],{"trials":2729,"activeCount":98},[],{"intervention":1784,"totalTrials":686,"cells":2731},{"EARLY_PHASE1":2732,"PHASE1":2734,"PHASE2":2736,"PHASE3":2742,"PHASE4":2744,"NA":2746},{"trials":2733,"activeCount":98},[],{"trials":2735,"activeCount":98},[],{"trials":2737,"activeCount":98},[2738],{"nctId":1776,"briefTitle":1777,"status":410,"phases":2739,"primaryCompletion":1779,"completion":1780,"start":1781,"enrollment":456,"conditions":2740,"interventions":2741},[87],[20],[218,1784,217,1785,139,1786,1787,1788,1739],{"trials":2743,"activeCount":98},[],{"trials":2745,"activeCount":98},[],{"trials":2747,"activeCount":98},[],{"intervention":1785,"totalTrials":686,"cells":2749},{"EARLY_PHASE1":2750,"PHASE1":2752,"PHASE2":2754,"PHASE3":2760,"PHASE4":2762,"NA":2764},{"trials":2751,"activeCount":98},[],{"trials":2753,"activeCount":98},[],{"trials":2755,"activeCount":98},[2756],{"nctId":1776,"briefTitle":1777,"status":410,"phases":2757,"primaryCompletion":1779,"completion":1780,"start":1781,"enrollment":456,"conditions":2758,"interventions":2759},[87],[20],[218,1784,217,1785,139,1786,1787,1788,1739],{"trials":2761,"activeCount":98},[],{"trials":2763,"activeCount":98},[],{"trials":2765,"activeCount":98},[],{"intervention":1787,"totalTrials":686,"cells":2767},{"EARLY_PHASE1":2768,"PHASE1":2770,"PHASE2":2772,"PHASE3":2778,"PHASE4":2780,"NA":2782},{"trials":2769,"activeCount":98},[],{"trials":2771,"activeCount":98},[],{"trials":2773,"activeCount":98},[2774],{"nctId":1776,"briefTitle":1777,"status":410,"phases":2775,"primaryCompletion":1779,"completion":1780,"start":1781,"enrollment":456,"conditions":2776,"interventions":2777},[87],[20],[218,1784,217,1785,139,1786,1787,1788,1739],{"trials":2779,"activeCount":98},[],{"trials":2781,"activeCount":98},[],{"trials":2783,"activeCount":98},[],{"intervention":1788,"totalTrials":686,"cells":2785},{"EARLY_PHASE1":2786,"PHASE1":2788,"PHASE2":2790,"PHASE3":2796,"PHASE4":2798,"NA":2800},{"trials":2787,"activeCount":98},[],{"trials":2789,"activeCount":98},[],{"trials":2791,"activeCount":98},[2792],{"nctId":1776,"briefTitle":1777,"status":410,"phases":2793,"primaryCompletion":1779,"completion":1780,"start":1781,"enrollment":456,"conditions":2794,"interventions":2795},[87],[20],[218,1784,217,1785,139,1786,1787,1788,1739],{"trials":2797,"activeCount":98},[],{"trials":2799,"activeCount":98},[],{"trials":2801,"activeCount":98},[],{"intervention":2803,"totalTrials":686,"cells":2804},"everolimus",{"EARLY_PHASE1":2805,"PHASE1":2807,"PHASE2":2809,"PHASE3":2820,"PHASE4":2822,"NA":2824},{"trials":2806,"activeCount":98},[],{"trials":2808,"activeCount":98},[],{"trials":2810,"activeCount":98},[2811],{"nctId":2812,"briefTitle":2813,"status":410,"phases":2814,"primaryCompletion":2815,"completion":2815,"start":2816,"enrollment":376,"conditions":2817,"interventions":2819},"NCT02031536","Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery",[87],"2017-07-19","2014-04-10",[473,474,475,2818,477,478,479],"Liver Metastases",[2803],{"trials":2821,"activeCount":98},[],{"trials":2823,"activeCount":98},[],{"trials":2825,"activeCount":98},[],{"intervention":216,"totalTrials":686,"cells":2827},{"EARLY_PHASE1":2828,"PHASE1":2830,"PHASE2":2832,"PHASE3":2838,"PHASE4":2840,"NA":2842},{"trials":2829,"activeCount":98},[],{"trials":2831,"activeCount":98},[],{"trials":2833,"activeCount":98},[2834],{"nctId":206,"briefTitle":207,"status":181,"phases":2835,"primaryCompletion":209,"completion":210,"start":211,"enrollment":212,"conditions":2836,"interventions":2837},[87],[214],[216,217,218,93,219,138,220],{"trials":2839,"activeCount":98},[],{"trials":2841,"activeCount":98},[],{"trials":2843,"activeCount":98},[],{"intervention":220,"totalTrials":686,"cells":2845},{"EARLY_PHASE1":2846,"PHASE1":2848,"PHASE2":2850,"PHASE3":2856,"PHASE4":2858,"NA":2860},{"trials":2847,"activeCount":98},[],{"trials":2849,"activeCount":98},[],{"trials":2851,"activeCount":98},[2852],{"nctId":206,"briefTitle":207,"status":181,"phases":2853,"primaryCompletion":209,"completion":210,"start":211,"enrollment":212,"conditions":2854,"interventions":2855},[87],[214],[216,217,218,93,219,138,220],{"trials":2857,"activeCount":98},[],{"trials":2859,"activeCount":98},[],{"trials":2861,"activeCount":98},[],{"intervention":257,"totalTrials":686,"cells":2863},{"EARLY_PHASE1":2864,"PHASE1":2866,"PHASE2":2868,"PHASE3":2874,"PHASE4":2876,"NA":2878},{"trials":2865,"activeCount":98},[],{"trials":2867,"activeCount":98},[],{"trials":2869,"activeCount":98},[2870],{"nctId":242,"briefTitle":243,"status":119,"phases":2871,"primaryCompletion":245,"completion":245,"start":246,"enrollment":98,"conditions":2872,"interventions":2873},[87],[161,162,163,248,249,250,167,168,169,171,251,252,253,254,255],[138,93,257],{"trials":2875,"activeCount":98},[],{"trials":2877,"activeCount":98},[],{"trials":2879,"activeCount":98},[],{"intervention":2881,"totalTrials":686,"cells":2882},"tamoxifen",{"EARLY_PHASE1":2883,"PHASE1":2885,"PHASE2":2887,"PHASE3":2899,"PHASE4":2901,"NA":2903},{"trials":2884,"activeCount":98},[],{"trials":2886,"activeCount":98},[],{"trials":2888,"activeCount":98},[2889],{"nctId":2890,"briefTitle":2891,"status":181,"phases":2892,"primaryCompletion":43,"completion":2893,"start":2894,"enrollment":2895,"conditions":2896,"interventions":2898},"NCT01124695","Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer",[87],"2022-12","2011-01-07",124,[27,2897],"Stage IV Breast Cancer",[2881],{"trials":2900,"activeCount":98},[],{"trials":2902,"activeCount":98},[],{"trials":2904,"activeCount":98},[],{"intervention":659,"totalTrials":686,"cells":2906},{"EARLY_PHASE1":2907,"PHASE1":2909,"PHASE2":2911,"PHASE3":2917,"PHASE4":2919,"NA":2921},{"trials":2908,"activeCount":98},[],{"trials":2910,"activeCount":98},[],{"trials":2912,"activeCount":98},[2913],{"nctId":649,"briefTitle":650,"status":181,"phases":2914,"primaryCompletion":652,"completion":413,"start":653,"enrollment":376,"conditions":2915,"interventions":2916},[86,87],[655,656],[658,659],{"trials":2918,"activeCount":98},[],{"trials":2920,"activeCount":98},[],{"trials":2922,"activeCount":98},[],{"intervention":2924,"totalTrials":686,"cells":2925},"Binimetinib",{"EARLY_PHASE1":2926,"PHASE1":2928,"PHASE2":2930,"PHASE3":2943,"PHASE4":2945,"NA":2947},{"trials":2927,"activeCount":98},[],{"trials":2929,"activeCount":98},[],{"trials":2931,"activeCount":98},[2932],{"nctId":2933,"briefTitle":2934,"status":410,"phases":2935,"primaryCompletion":2936,"completion":667,"start":2937,"enrollment":33,"conditions":2938,"interventions":2941},"NCT04221438","Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement",[87],"2024-06-10","2021-09-22",[787,2939,788,789,790,2940],"Metastatic Malignant Neoplasm in Lymph Node","Recurrent Cutaneous Melanoma",[2924,2942],"Encorafenib",{"trials":2944,"activeCount":98},[],{"trials":2946,"activeCount":98},[],{"trials":2948,"activeCount":98},[],{"intervention":2942,"totalTrials":686,"cells":2950},{"EARLY_PHASE1":2951,"PHASE1":2953,"PHASE2":2955,"PHASE3":2961,"PHASE4":2963,"NA":2965},{"trials":2952,"activeCount":98},[],{"trials":2954,"activeCount":98},[],{"trials":2956,"activeCount":98},[2957],{"nctId":2933,"briefTitle":2934,"status":410,"phases":2958,"primaryCompletion":2936,"completion":667,"start":2937,"enrollment":33,"conditions":2959,"interventions":2960},[87],[787,2939,788,789,790,2940],[2924,2942],{"trials":2962,"activeCount":98},[],{"trials":2964,"activeCount":98},[],{"trials":2966,"activeCount":98},[],{"intervention":324,"totalTrials":2968,"cells":2969},13,{"EARLY_PHASE1":2970,"PHASE1":2972,"PHASE2":2974,"PHASE3":2976,"PHASE4":2978,"NA":2980},{"trials":2971,"activeCount":98},[],{"trials":2973,"activeCount":98},[],{"trials":2975,"activeCount":98},[],{"trials":2977,"activeCount":98},[],{"trials":2979,"activeCount":98},[],{"trials":2981,"activeCount":98},[2982,2991,3000,3010,3019,3023,3033,3043,3053,3057,3061,3071,3080],{"nctId":2983,"briefTitle":2984,"status":181,"phases":2985,"primaryCompletion":2986,"completion":2986,"start":2987,"enrollment":2988,"conditions":2989,"interventions":2990},"NCT00896909","HER-2 Mutations in Tumor Samples From Patients With Advanced Non-Small Cell Lung Cancer Treated on Clinical Trial ECOG-2598",[],"2006-07-02","2006-02-02",44,[14],[324,325,591],{"nctId":2992,"briefTitle":2993,"status":181,"phases":2994,"primaryCompletion":2995,"completion":2995,"start":2996,"enrollment":2997,"conditions":2998,"interventions":2999},"NCT01505712","Biomarkers in Tissue Samples From Patients With Hodgkin Lymphoma Enrolled on ECOG-2496 Clinical Trial",[],"2012-11-19","2011-12-15",393,[20],[324],{"nctId":3001,"briefTitle":3002,"status":181,"phases":3003,"primaryCompletion":3004,"completion":3004,"start":3005,"enrollment":3006,"conditions":3007,"interventions":3008},"NCT01209299","Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate",[],"2012-02-19","2012-01-19",80,[22],[3009,324],"DNA methylation analysis",{"nctId":3011,"briefTitle":3012,"status":181,"phases":3013,"primaryCompletion":3014,"completion":3014,"start":3015,"enrollment":3016,"conditions":3017,"interventions":3018},"NCT01131208","Biomarkers in Patients With Diffuse Large B-Cell Lymphoma Treated With Combination Chemotherapy With or Without Rituximab",[],"2010-08-21","2010-04-21",200,[20],[324],{"nctId":1198,"briefTitle":1199,"status":181,"phases":3020,"primaryCompletion":1201,"completion":1201,"start":1202,"enrollment":1203,"conditions":3021,"interventions":3022},[],[20],[709,323,324,592],{"nctId":3024,"briefTitle":3025,"status":181,"phases":3026,"primaryCompletion":3027,"completion":3027,"start":3028,"enrollment":3016,"conditions":3029,"interventions":3030},"NCT00897754","Gene Expression in Patients With Advanced or Metastatic Colorectal Cancer Receiving Bevacizumab",[],"2009-02-01","2007-07-24",[417],[324,3031,3032],"protein expression analysis","reverse transcriptase-polymerase chain reaction",{"nctId":3034,"briefTitle":3035,"status":181,"phases":3036,"primaryCompletion":3037,"completion":3037,"start":3038,"enrollment":3039,"conditions":3040,"interventions":3041},"NCT01132560","Biomarkers in Tissue Samples From Patients With Ductal Breast Carcinoma in Situ",[],"2010-04-05","2010-03-05",500,[27],[3042,324,3032],"RNA analysis",{"nctId":3044,"briefTitle":3045,"status":181,"phases":3046,"primaryCompletion":3047,"completion":3047,"start":3048,"enrollment":3049,"conditions":3050,"interventions":3051},"NCT00937781","Study of Tumor Tissue From Patients With Melanoma Treated on Clinical Trial EST-1690",[],"2011-08-08","2011-02-08",307,[22],[3042,324,3052,591],"microarray analysis",{"nctId":315,"briefTitle":316,"status":181,"phases":3054,"primaryCompletion":318,"completion":318,"start":319,"enrollment":320,"conditions":3055,"interventions":3056},[],[25],[190,44,323,324,325],{"nctId":583,"briefTitle":584,"status":181,"phases":3058,"primaryCompletion":586,"completion":586,"start":587,"enrollment":588,"conditions":3059,"interventions":3060},[],[14],[450,115,204,324,591,592],{"nctId":3062,"briefTitle":3063,"status":181,"phases":3064,"primaryCompletion":3065,"completion":3065,"start":3066,"enrollment":11,"conditions":3067,"interventions":3068},"NCT01194635","Biomarkers of Response in Blood and Tumor Tissue Samples From Patients With Unresectable Stage IV Squamous Cell Cancer of the Head and Neck Previously Treated With Cetuximab, Cisplatin, and Radiation Therapy",[],"2010-09-05","2010-08-05",[25],[3069,324,591,3070,3031],"fluorescence in situ hybridization","protein analysis",{"nctId":3072,"briefTitle":3073,"status":181,"phases":3074,"primaryCompletion":3075,"completion":3075,"start":3076,"enrollment":3077,"conditions":3078,"interventions":3079},"NCT01156168","Biomarkers in Tissue Samples From Patients With Breast Cancer Treated With Bevacizumab",[],"2011-09-08","2011-04-05",363,[27],[323,324,592,3031],{"nctId":3081,"briefTitle":3082,"status":181,"phases":3083,"primaryCompletion":3084,"completion":3084,"start":3085,"enrollment":3086,"conditions":3087,"interventions":3088},"NCT00898963","Biomarkers in Patients With Stage III or Stage IV Follicular Lymphoma Treated on Clinical Trial E-1496",[],"2011-02-11","2007-04-18",175,[20],[324,3052,592],{"intervention":592,"totalTrials":15,"cells":3090},{"EARLY_PHASE1":3091,"PHASE1":3093,"PHASE2":3095,"PHASE3":3097,"PHASE4":3099,"NA":3101},{"trials":3092,"activeCount":98},[],{"trials":3094,"activeCount":98},[],{"trials":3096,"activeCount":98},[],{"trials":3098,"activeCount":98},[],{"trials":3100,"activeCount":98},[],{"trials":3102,"activeCount":98},[3103,3113,3117,3127,3137,3141,3150,3154,3165],{"nctId":3104,"briefTitle":3105,"status":181,"phases":3106,"primaryCompletion":3107,"completion":3107,"start":3108,"enrollment":3109,"conditions":3110,"interventions":3112},"NCT00899184","DNA Changes in Patients With Prostate Cancer",[],"2007-05-30","2006-05-23",646,[3111],"Prostate Cancer",[592],{"nctId":1198,"briefTitle":1199,"status":181,"phases":3114,"primaryCompletion":1201,"completion":1201,"start":1202,"enrollment":1203,"conditions":3115,"interventions":3116},[],[20],[709,323,324,592],{"nctId":3118,"briefTitle":3119,"status":181,"phases":3120,"primaryCompletion":3121,"completion":3121,"start":3122,"enrollment":3123,"conditions":3124,"interventions":3126},"NCT00898040","Study of DNA Samples From Patients With Multiple Myeloma",[],"2007-01-01","2006-07-06",600,[3125],"Multiple Myeloma and Plasma Cell Neoplasm",[592],{"nctId":3128,"briefTitle":3129,"status":181,"phases":3130,"primaryCompletion":3131,"completion":3131,"start":3132,"enrollment":3133,"conditions":3134,"interventions":3135},"NCT00897533","Development of a Model to Predict Progression-Free Survival After Erlotinib in Patients With Non-Small Cell Lung Cancer",[],"2008-04-13","2007-04-13",137,[14],[3136,592],"gene mapping",{"nctId":583,"briefTitle":584,"status":181,"phases":3138,"primaryCompletion":586,"completion":586,"start":587,"enrollment":588,"conditions":3139,"interventions":3140},[],[14],[450,115,204,324,591,592],{"nctId":3142,"briefTitle":3143,"status":181,"phases":3144,"primaryCompletion":3145,"completion":3145,"start":3146,"enrollment":3147,"conditions":3148,"interventions":3149},"NCT00897351","Study of Tissue and Blood Samples From Patients With Recurrent Prostate Cancer Who Received Lapatinib on Clinical Trial ECOG-E5803",[],"2009-02-10","2008-07-10",37,[3111],[325,592,3031],{"nctId":3072,"briefTitle":3073,"status":181,"phases":3151,"primaryCompletion":3075,"completion":3075,"start":3076,"enrollment":3077,"conditions":3152,"interventions":3153},[],[27],[323,324,592,3031],{"nctId":3155,"briefTitle":3156,"status":181,"phases":3157,"primaryCompletion":3158,"completion":3158,"start":3159,"enrollment":3160,"conditions":3161,"interventions":3163},"NCT00898495","Genes in Predicting Outcome in Patients With Esophageal Cancer Treated With Cisplatin, Radiation Therapy, and Surgery",[],"2008-12-31","2007-05-11",118,[3162],"Esophageal Cancer",[3164,591,592],"loss of heterozygosity analysis",{"nctId":3081,"briefTitle":3082,"status":181,"phases":3166,"primaryCompletion":3084,"completion":3084,"start":3085,"enrollment":3086,"conditions":3167,"interventions":3168},[],[20],[324,3052,592],{"intervention":325,"totalTrials":18,"cells":3170},{"EARLY_PHASE1":3171,"PHASE1":3173,"PHASE2":3175,"PHASE3":3177,"PHASE4":3179,"NA":3181},{"trials":3172,"activeCount":98},[],{"trials":3174,"activeCount":98},[],{"trials":3176,"activeCount":98},[],{"trials":3178,"activeCount":98},[],{"trials":3180,"activeCount":98},[],{"trials":3182,"activeCount":98},[3183,3192,3196,3204,3208,3212,3224],{"nctId":3184,"briefTitle":3185,"status":181,"phases":3186,"primaryCompletion":3187,"completion":3187,"start":3188,"enrollment":3189,"conditions":3190,"interventions":3191},"NCT01251159","Biomarkers in Bone Marrow Samples From Patients With Acute Myeloid Leukemia",[],"2009-06-15","2009-05-15",30,[17],[325,591],{"nctId":2983,"briefTitle":2984,"status":181,"phases":3193,"primaryCompletion":2986,"completion":2986,"start":2987,"enrollment":2988,"conditions":3194,"interventions":3195},[],[14],[324,325,591],{"nctId":3197,"briefTitle":3198,"status":181,"phases":3199,"primaryCompletion":3200,"completion":3200,"start":3201,"enrollment":3006,"conditions":3202,"interventions":3203},"NCT01124669","Biomarkers in Blood Samples From Patients With Refractory Non-Small Cell Lung Cancer Previously Treated With Sorafenib Tosylate",[],"2010-07-13","2010-06-13",[14],[323,325],{"nctId":315,"briefTitle":316,"status":181,"phases":3205,"primaryCompletion":318,"completion":318,"start":319,"enrollment":320,"conditions":3206,"interventions":3207},[],[25],[190,44,323,324,325],{"nctId":3142,"briefTitle":3143,"status":181,"phases":3209,"primaryCompletion":3145,"completion":3145,"start":3146,"enrollment":3147,"conditions":3210,"interventions":3211},[],[3111],[325,592,3031],{"nctId":3213,"briefTitle":3214,"status":181,"phases":3215,"primaryCompletion":3216,"completion":3217,"start":3218,"enrollment":3219,"conditions":3220,"interventions":3221},"NCT00002695","Analysis of Tumor Tissue and Lymph Nodes Surgically Removed From Patients With Cancers of the Head and Neck",[],"2002-10-18","2011-05-27","1996-04-30",530,[25],[3222,3223,325],"DNA stability analysis","microsatellite instability analysis",{"nctId":3225,"briefTitle":3226,"status":181,"phases":3227,"primaryCompletion":3228,"completion":3228,"start":3229,"enrollment":3230,"conditions":3231,"interventions":3232},"NCT00899366","DNA Analysis of Tissue From Patients With T-Cell Acute Lymphoblastic Leukemia",[],"2009-07-30","2006-12-28",49,[17],[3052,325],{"intervention":591,"totalTrials":18,"cells":3234},{"EARLY_PHASE1":3235,"PHASE1":3237,"PHASE2":3239,"PHASE3":3241,"PHASE4":3243,"NA":3245},{"trials":3236,"activeCount":98},[],{"trials":3238,"activeCount":98},[],{"trials":3240,"activeCount":98},[],{"trials":3242,"activeCount":98},[],{"trials":3244,"activeCount":98},[],{"trials":3246,"activeCount":98},[3247,3251,3255,3259,3263,3267,3277],{"nctId":3184,"briefTitle":3185,"status":181,"phases":3248,"primaryCompletion":3187,"completion":3187,"start":3188,"enrollment":3189,"conditions":3249,"interventions":3250},[],[17],[325,591],{"nctId":2983,"briefTitle":2984,"status":181,"phases":3252,"primaryCompletion":2986,"completion":2986,"start":2987,"enrollment":2988,"conditions":3253,"interventions":3254},[],[14],[324,325,591],{"nctId":3044,"briefTitle":3045,"status":181,"phases":3256,"primaryCompletion":3047,"completion":3047,"start":3048,"enrollment":3049,"conditions":3257,"interventions":3258},[],[22],[3042,324,3052,591],{"nctId":583,"briefTitle":584,"status":181,"phases":3260,"primaryCompletion":586,"completion":586,"start":587,"enrollment":588,"conditions":3261,"interventions":3262},[],[14],[450,115,204,324,591,592],{"nctId":3062,"briefTitle":3063,"status":181,"phases":3264,"primaryCompletion":3065,"completion":3065,"start":3066,"enrollment":11,"conditions":3265,"interventions":3266},[],[25],[3069,324,591,3070,3031],{"nctId":3268,"briefTitle":3269,"status":181,"phases":3270,"primaryCompletion":3271,"completion":3271,"start":3272,"enrollment":3273,"conditions":3274,"interventions":3275},"NCT00897936","DNA Analysis of Tumor Tissue From Patients With Acute Myeloid Leukemia",[],"2009-10-15","2006-03-23",418,[17],[3009,3276,3069,3052,591],"comparative genomic hybridization",{"nctId":3155,"briefTitle":3156,"status":181,"phases":3278,"primaryCompletion":3158,"completion":3158,"start":3159,"enrollment":3160,"conditions":3279,"interventions":3280},[],[3162],[3164,591,592],{"intervention":3052,"totalTrials":456,"cells":3282},{"EARLY_PHASE1":3283,"PHASE1":3285,"PHASE2":3287,"PHASE3":3289,"PHASE4":3291,"NA":3293},{"trials":3284,"activeCount":98},[],{"trials":3286,"activeCount":98},[],{"trials":3288,"activeCount":98},[],{"trials":3290,"activeCount":98},[],{"trials":3292,"activeCount":98},[],{"trials":3294,"activeCount":98},[3295,3304,3312,3316,3320,3324],{"nctId":3296,"briefTitle":3297,"status":181,"phases":3298,"primaryCompletion":3299,"completion":3299,"start":3300,"enrollment":3301,"conditions":3302,"interventions":3303},"NCT00897845","Studying Tumor Samples From Women Who Have Undergone Chemotherapy for Breast Cancer",[],"2013-12-02","2008-06-17",2541,[27],[3042,3052],{"nctId":3305,"briefTitle":3306,"status":181,"phases":3307,"primaryCompletion":3308,"completion":3308,"start":3309,"enrollment":3133,"conditions":3310,"interventions":3311},"NCT00898261","Gene Expression in Tissue From Patients With Acute Lymphoblastic Leukemia",[],"2012-07-19","2007-10-26",[17],[3052,3032],{"nctId":3044,"briefTitle":3045,"status":181,"phases":3313,"primaryCompletion":3047,"completion":3047,"start":3048,"enrollment":3049,"conditions":3314,"interventions":3315},[],[22],[3042,324,3052,591],{"nctId":3268,"briefTitle":3269,"status":181,"phases":3317,"primaryCompletion":3271,"completion":3271,"start":3272,"enrollment":3273,"conditions":3318,"interventions":3319},[],[17],[3009,3276,3069,3052,591],{"nctId":3225,"briefTitle":3226,"status":181,"phases":3321,"primaryCompletion":3228,"completion":3228,"start":3229,"enrollment":3230,"conditions":3322,"interventions":3323},[],[17],[3052,325],{"nctId":3081,"briefTitle":3082,"status":181,"phases":3325,"primaryCompletion":3084,"completion":3084,"start":3085,"enrollment":3086,"conditions":3326,"interventions":3327},[],[20],[324,3052,592],{"intervention":323,"totalTrials":28,"cells":3329},{"EARLY_PHASE1":3330,"PHASE1":3332,"PHASE2":3334,"PHASE3":3336,"PHASE4":3338,"NA":3340},{"trials":3331,"activeCount":98},[],{"trials":3333,"activeCount":98},[],{"trials":3335,"activeCount":98},[],{"trials":3337,"activeCount":98},[],{"trials":3339,"activeCount":98},[],{"trials":3341,"activeCount":98},[3342,3346,3350,3354],{"nctId":1198,"briefTitle":1199,"status":181,"phases":3343,"primaryCompletion":1201,"completion":1201,"start":1202,"enrollment":1203,"conditions":3344,"interventions":3345},[],[20],[709,323,324,592],{"nctId":3197,"briefTitle":3198,"status":181,"phases":3347,"primaryCompletion":3200,"completion":3200,"start":3201,"enrollment":3006,"conditions":3348,"interventions":3349},[],[14],[323,325],{"nctId":315,"briefTitle":316,"status":181,"phases":3351,"primaryCompletion":318,"completion":318,"start":319,"enrollment":320,"conditions":3352,"interventions":3353},[],[25],[190,44,323,324,325],{"nctId":3072,"briefTitle":3073,"status":181,"phases":3355,"primaryCompletion":3075,"completion":3075,"start":3076,"enrollment":3077,"conditions":3356,"interventions":3357},[],[27],[323,324,592,3031],{"intervention":3031,"totalTrials":28,"cells":3359},{"EARLY_PHASE1":3360,"PHASE1":3362,"PHASE2":3364,"PHASE3":3366,"PHASE4":3368,"NA":3370},{"trials":3361,"activeCount":98},[],{"trials":3363,"activeCount":98},[],{"trials":3365,"activeCount":98},[],{"trials":3367,"activeCount":98},[],{"trials":3369,"activeCount":98},[],{"trials":3371,"activeCount":98},[3372,3376,3380,3384],{"nctId":3024,"briefTitle":3025,"status":181,"phases":3373,"primaryCompletion":3027,"completion":3027,"start":3028,"enrollment":3016,"conditions":3374,"interventions":3375},[],[417],[324,3031,3032],{"nctId":3142,"briefTitle":3143,"status":181,"phases":3377,"primaryCompletion":3145,"completion":3145,"start":3146,"enrollment":3147,"conditions":3378,"interventions":3379},[],[3111],[325,592,3031],{"nctId":3062,"briefTitle":3063,"status":181,"phases":3381,"primaryCompletion":3065,"completion":3065,"start":3066,"enrollment":11,"conditions":3382,"interventions":3383},[],[25],[3069,324,591,3070,3031],{"nctId":3072,"briefTitle":3073,"status":181,"phases":3385,"primaryCompletion":3075,"completion":3075,"start":3076,"enrollment":3077,"conditions":3386,"interventions":3387},[],[27],[323,324,592,3031],{"intervention":3042,"totalTrials":33,"cells":3389},{"EARLY_PHASE1":3390,"PHASE1":3392,"PHASE2":3394,"PHASE3":3396,"PHASE4":3398,"NA":3400},{"trials":3391,"activeCount":98},[],{"trials":3393,"activeCount":98},[],{"trials":3395,"activeCount":98},[],{"trials":3397,"activeCount":98},[],{"trials":3399,"activeCount":98},[],{"trials":3401,"activeCount":98},[3402,3406,3410],{"nctId":3296,"briefTitle":3297,"status":181,"phases":3403,"primaryCompletion":3299,"completion":3299,"start":3300,"enrollment":3301,"conditions":3404,"interventions":3405},[],[27],[3042,3052],{"nctId":3034,"briefTitle":3035,"status":181,"phases":3407,"primaryCompletion":3037,"completion":3037,"start":3038,"enrollment":3039,"conditions":3408,"interventions":3409},[],[27],[3042,324,3032],{"nctId":3044,"briefTitle":3045,"status":181,"phases":3411,"primaryCompletion":3047,"completion":3047,"start":3048,"enrollment":3049,"conditions":3412,"interventions":3413},[],[22],[3042,324,3052,591],{"intervention":581,"totalTrials":33,"cells":3415},{"EARLY_PHASE1":3416,"PHASE1":3418,"PHASE2":3420,"PHASE3":3422,"PHASE4":3424,"NA":3426},{"trials":3417,"activeCount":98},[],{"trials":3419,"activeCount":98},[],{"trials":3421,"activeCount":98},[],{"trials":3423,"activeCount":98},[],{"trials":3425,"activeCount":98},[],{"trials":3427,"activeCount":98},[3428,3437,3445],{"nctId":3429,"briefTitle":3430,"status":181,"phases":3431,"primaryCompletion":3432,"completion":3432,"start":3433,"enrollment":767,"conditions":3434,"interventions":3435},"NCT00897520","Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy",[],"2010-01-24","2008-01-14",[22],[3436,581],"recombinant interferon alfa",{"nctId":3438,"briefTitle":3439,"status":181,"phases":3440,"primaryCompletion":3441,"completion":3441,"start":3442,"enrollment":3016,"conditions":3443,"interventions":3444},"NCT01169363","Biomarkers in Bone Marrow and Blood Samples From Older Patients With Acute Myeloid Leukemia Treated With Cytarabine-Based Therapy",[],"2010-08-08","2010-07-08",[17],[581],{"nctId":573,"briefTitle":574,"status":181,"phases":3446,"primaryCompletion":576,"completion":576,"start":577,"enrollment":578,"conditions":3447,"interventions":3448},[],[14],[450,115,204,581],{"intervention":3009,"totalTrials":33,"cells":3450},{"EARLY_PHASE1":3451,"PHASE1":3453,"PHASE2":3455,"PHASE3":3457,"PHASE4":3459,"NA":3461},{"trials":3452,"activeCount":98},[],{"trials":3454,"activeCount":98},[],{"trials":3456,"activeCount":98},[],{"trials":3458,"activeCount":98},[],{"trials":3460,"activeCount":98},[],{"trials":3462,"activeCount":98},[3463,3467,3476],{"nctId":3001,"briefTitle":3002,"status":181,"phases":3464,"primaryCompletion":3004,"completion":3004,"start":3005,"enrollment":3006,"conditions":3465,"interventions":3466},[],[22],[3009,324],{"nctId":3468,"briefTitle":3469,"status":181,"phases":3470,"primaryCompletion":3471,"completion":3471,"start":3472,"enrollment":3473,"conditions":3474,"interventions":3475},"NCT00897819","Studying DNA and Outcome in Patients With Advanced Colorectal Cancer Treated With Fluorouracil and Oxaliplatin With or Without Bevacizumab on Clinial Trial E-3200",[],"2008-01-30","2007-01-03",350,[417],[3009,3164,3223],{"nctId":3268,"briefTitle":3269,"status":181,"phases":3477,"primaryCompletion":3271,"completion":3271,"start":3272,"enrollment":3273,"conditions":3478,"interventions":3479},[],[17],[3009,3276,3069,3052,591],{"intervention":3032,"totalTrials":33,"cells":3481},{"EARLY_PHASE1":3482,"PHASE1":3484,"PHASE2":3486,"PHASE3":3488,"PHASE4":3490,"NA":3492},{"trials":3483,"activeCount":98},[],{"trials":3485,"activeCount":98},[],{"trials":3487,"activeCount":98},[],{"trials":3489,"activeCount":98},[],{"trials":3491,"activeCount":98},[],{"trials":3493,"activeCount":98},[3494,3498,3502],{"nctId":3305,"briefTitle":3306,"status":181,"phases":3495,"primaryCompletion":3308,"completion":3308,"start":3309,"enrollment":3133,"conditions":3496,"interventions":3497},[],[17],[3052,3032],{"nctId":3024,"briefTitle":3025,"status":181,"phases":3499,"primaryCompletion":3027,"completion":3027,"start":3028,"enrollment":3016,"conditions":3500,"interventions":3501},[],[417],[324,3031,3032],{"nctId":3034,"briefTitle":3035,"status":181,"phases":3503,"primaryCompletion":3037,"completion":3037,"start":3038,"enrollment":3039,"conditions":3504,"interventions":3505},[],[27],[3042,324,3032],{"intervention":3164,"totalTrials":376,"cells":3507},{"EARLY_PHASE1":3508,"PHASE1":3510,"PHASE2":3512,"PHASE3":3514,"PHASE4":3516,"NA":3518},{"trials":3509,"activeCount":98},[],{"trials":3511,"activeCount":98},[],{"trials":3513,"activeCount":98},[],{"trials":3515,"activeCount":98},[],{"trials":3517,"activeCount":98},[],{"trials":3519,"activeCount":98},[3520,3524],{"nctId":3468,"briefTitle":3469,"status":181,"phases":3521,"primaryCompletion":3471,"completion":3471,"start":3472,"enrollment":3473,"conditions":3522,"interventions":3523},[],[417],[3009,3164,3223],{"nctId":3155,"briefTitle":3156,"status":181,"phases":3525,"primaryCompletion":3158,"completion":3158,"start":3159,"enrollment":3160,"conditions":3526,"interventions":3527},[],[3162],[3164,591,592],{"intervention":3223,"totalTrials":376,"cells":3529},{"EARLY_PHASE1":3530,"PHASE1":3532,"PHASE2":3534,"PHASE3":3536,"PHASE4":3538,"NA":3540},{"trials":3531,"activeCount":98},[],{"trials":3533,"activeCount":98},[],{"trials":3535,"activeCount":98},[],{"trials":3537,"activeCount":98},[],{"trials":3539,"activeCount":98},[],{"trials":3541,"activeCount":98},[3542,3546],{"nctId":3468,"briefTitle":3469,"status":181,"phases":3543,"primaryCompletion":3471,"completion":3471,"start":3472,"enrollment":3473,"conditions":3544,"interventions":3545},[],[417],[3009,3164,3223],{"nctId":3213,"briefTitle":3214,"status":181,"phases":3547,"primaryCompletion":3216,"completion":3217,"start":3218,"enrollment":3219,"conditions":3548,"interventions":3549},[],[25],[3222,3223,325],{"intervention":3069,"totalTrials":376,"cells":3551},{"EARLY_PHASE1":3552,"PHASE1":3554,"PHASE2":3556,"PHASE3":3558,"PHASE4":3560,"NA":3562},{"trials":3553,"activeCount":98},[],{"trials":3555,"activeCount":98},[],{"trials":3557,"activeCount":98},[],{"trials":3559,"activeCount":98},[],{"trials":3561,"activeCount":98},[],{"trials":3563,"activeCount":98},[3564,3568],{"nctId":3062,"briefTitle":3063,"status":181,"phases":3565,"primaryCompletion":3065,"completion":3065,"start":3066,"enrollment":11,"conditions":3566,"interventions":3567},[],[25],[3069,324,591,3070,3031],{"nctId":3268,"briefTitle":3269,"status":181,"phases":3569,"primaryCompletion":3271,"completion":3271,"start":3272,"enrollment":3273,"conditions":3570,"interventions":3571},[],[17],[3009,3276,3069,3052,591],{"intervention":3436,"totalTrials":686,"cells":3573},{"EARLY_PHASE1":3574,"PHASE1":3576,"PHASE2":3578,"PHASE3":3580,"PHASE4":3582,"NA":3584},{"trials":3575,"activeCount":98},[],{"trials":3577,"activeCount":98},[],{"trials":3579,"activeCount":98},[],{"trials":3581,"activeCount":98},[],{"trials":3583,"activeCount":98},[],{"trials":3585,"activeCount":98},[3586],{"nctId":3429,"briefTitle":3430,"status":181,"phases":3587,"primaryCompletion":3432,"completion":3432,"start":3433,"enrollment":767,"conditions":3588,"interventions":3589},[],[22],[3436,581],{"intervention":3591,"totalTrials":686,"cells":3592},"cytogenetic analysis",{"EARLY_PHASE1":3593,"PHASE1":3595,"PHASE2":3597,"PHASE3":3599,"PHASE4":3601,"NA":3603},{"trials":3594,"activeCount":98},[],{"trials":3596,"activeCount":98},[],{"trials":3598,"activeCount":98},[],{"trials":3600,"activeCount":98},[],{"trials":3602,"activeCount":98},[],{"trials":3604,"activeCount":98},[3605],{"nctId":3606,"briefTitle":3607,"status":181,"phases":3608,"primaryCompletion":3609,"completion":3609,"start":3610,"enrollment":3611,"conditions":3612,"interventions":3613},"NCT00899873","Biomarkers in Samples From Patients With Chronic Lymphocytic Leukemia Treated on Clinical Trial ECOG-2997",[],"2012-07-17","2012-04-17",225,[17],[3591],{"intervention":3136,"totalTrials":686,"cells":3615},{"EARLY_PHASE1":3616,"PHASE1":3618,"PHASE2":3620,"PHASE3":3622,"PHASE4":3624,"NA":3626},{"trials":3617,"activeCount":98},[],{"trials":3619,"activeCount":98},[],{"trials":3621,"activeCount":98},[],{"trials":3623,"activeCount":98},[],{"trials":3625,"activeCount":98},[],{"trials":3627,"activeCount":98},[3628],{"nctId":3128,"briefTitle":3129,"status":181,"phases":3629,"primaryCompletion":3131,"completion":3131,"start":3132,"enrollment":3133,"conditions":3630,"interventions":3631},[],[14],[3136,592],{"intervention":3633,"totalTrials":686,"cells":3634},"Nicotine Replacement",{"EARLY_PHASE1":3635,"PHASE1":3637,"PHASE2":3639,"PHASE3":3641,"PHASE4":3643,"NA":3645},{"trials":3636,"activeCount":98},[],{"trials":3638,"activeCount":98},[],{"trials":3640,"activeCount":98},[],{"trials":3642,"activeCount":98},[],{"trials":3644,"activeCount":98},[],{"trials":3646,"activeCount":98},[3647],{"nctId":3648,"briefTitle":3649,"status":181,"phases":3650,"primaryCompletion":3651,"completion":3651,"start":3652,"enrollment":3653,"conditions":3654,"interventions":3661},"NCT03808818","Implementing a Virtual Tobacco Treatment for Cancer Patients in Community Oncology Practices",[90],"2023-12-31","2019-08-01",306,[3655,3656,3657,3658,3659,3660],"Carcinoma In Situ","Current Smoker","Malignant Neoplasm","Primary Neoplasm","Recurrent Neoplasm","Smoking Cessation",[3633],{"intervention":3070,"totalTrials":686,"cells":3663},{"EARLY_PHASE1":3664,"PHASE1":3666,"PHASE2":3668,"PHASE3":3670,"PHASE4":3672,"NA":3674},{"trials":3665,"activeCount":98},[],{"trials":3667,"activeCount":98},[],{"trials":3669,"activeCount":98},[],{"trials":3671,"activeCount":98},[],{"trials":3673,"activeCount":98},[],{"trials":3675,"activeCount":98},[3676],{"nctId":3062,"briefTitle":3063,"status":181,"phases":3677,"primaryCompletion":3065,"completion":3065,"start":3066,"enrollment":11,"conditions":3678,"interventions":3679},[],[25],[3069,324,591,3070,3031],{"intervention":3276,"totalTrials":686,"cells":3681},{"EARLY_PHASE1":3682,"PHASE1":3684,"PHASE2":3686,"PHASE3":3688,"PHASE4":3690,"NA":3692},{"trials":3683,"activeCount":98},[],{"trials":3685,"activeCount":98},[],{"trials":3687,"activeCount":98},[],{"trials":3689,"activeCount":98},[],{"trials":3691,"activeCount":98},[],{"trials":3693,"activeCount":98},[3694],{"nctId":3268,"briefTitle":3269,"status":181,"phases":3695,"primaryCompletion":3271,"completion":3271,"start":3272,"enrollment":3273,"conditions":3696,"interventions":3697},[],[17],[3009,3276,3069,3052,591],{"intervention":3222,"totalTrials":686,"cells":3699},{"EARLY_PHASE1":3700,"PHASE1":3702,"PHASE2":3704,"PHASE3":3706,"PHASE4":3708,"NA":3710},{"trials":3701,"activeCount":98},[],{"trials":3703,"activeCount":98},[],{"trials":3705,"activeCount":98},[],{"trials":3707,"activeCount":98},[],{"trials":3709,"activeCount":98},[],{"trials":3711,"activeCount":98},[3712],{"nctId":3213,"briefTitle":3214,"status":181,"phases":3713,"primaryCompletion":3216,"completion":3217,"start":3218,"enrollment":3219,"conditions":3714,"interventions":3715},[],[25],[3222,3223,325]]